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Introduction and outline of the thesis 
In the past years, peripheral nerve block has rapidly gained popularity as an anesthetic 
technique for i.a. upper and lower extremity orthopedic surgery. It is popular among 
anesthesiologists and patients for peri- and postoperative pain relief. By blocking speci!c 
nerves to the limb that is to be operated, locoregional anesthesia and analgesia can be 
achieved. The choice of anesthetic technique is determined by patient comorbidities and 
by obtaining an informed consent that includes understanding all available options and 
their risks and bene!ts. Compared to general anesthesia or central neuraxis blockade, 
interference of peripheral nerve block with vital functions is minimal and postoperative 
analgesia is excellent. If a patient has signi!cant comorbidity, peripheral nerve block may 
have advantages over general anesthesia, e.g. the use of axillary block for hand surgery in a 
respiratory cripple. 
Regional anesthetic techniques play an important role in providing postoperative analgesia, 
decreasing the incidence of perioperative thromboembolic complications and facilitating 
early rehabilitation and hospital discharges. The use of peripheral nerve blocks is increasing; 
they are being used as the primary and sole anesthetic technique to facilitate painless 
surgery whether or not supplemented with sedation or a ‘light’ general anesthetic, with the 
airway protected with a laryngeal mask airway. Regional anesthesia may also be instituted 
preoperatively with the sole objective of postoperative analgesia. 
“Regional anesthesia always works, provided you put the right dose of the right drug in 
the right place.”1 This chapter provides some background information about the relevant 
anatomy and the techniques and local anesthetics used for regional anesthesia. This thesis 
discusses different factors determining the duration of peripheral nerve block.
Anatomy 
Surgical anesthesia of the upper extremity and shoulder can be obtained by neural blockade 
of the brachial plexus (C5-Th1) or its terminal branches at several sites. The brachial plexus 
(Figure 1) is formed by the union of the anterior primary divisions (ventral rami) of the !fth 
through the eighth cervical roots and the !rst thoracic root (A). As the nerve roots leave the 
intervertebral foramina, they converge, forming trunks, divisions, cords, and then !nally 
terminal nerves. Three distinct trunks are formed between the anterior and middle scalene 
muscles. Because they are vertically arranged, they are termed superior, middle and inferior 
(B). As the trunks pass over the lateral border of the !rst rib and under the clavicle, each 
trunk divides into anterior and posterior divisions (C). As the brachial plexus emerges below 
the clavicle, the !bers combine again to form three cords that are named according to their 
relationship to the subclavian artery: lateral, medial, and posterior (D). At the lateral border 
of the pectoralis minor muscle, each cord gives off a large branch before terminating as a 
major terminal nerve (E). The lateral cord gives off the lateral branch of the median nerve 
and terminates as the musculocutaneous nerve; the medial cord gives off the medial branch 
of the median nerve and terminates as the ulnar nerve; and the posterior cord gives off the 
axillary nerve and terminates as the radial nerve.
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The lumbar and sacral plexuses are the major nerve distributions to the lower extremities. 
The lumbar plexus is derived from the ventral rami of L1-L4, with some occasional 
contribution from T12 (Figure 2, 3). The lumbar plexus, forms three major nerves that 
innervate the lower extremity: the lateral femoral cutaneous, femoral and obturator nerves. 
These nerves predominantly supply motor and sensory innervation to the anterior portion of 
the lower extremity and the cutaneous sensory portion of the medial lower leg (saphenous 
nerve). The femoral nerve runs between the psoas and iliacus muscles to enter the thigh 
beneath the inguinal ligament, 1-2 cm lateral to the femoral artery and at a slightly greater 
depth. 
The sacral plexus is derived from the nerve roots of L4-L5 and S1-S3 (Figure 2, 3). It primarily 
forms the sciatic nerve, which passes through the greater sciatic foramen and descends 
in the posterior thigh to the popliteal fossa, where it divides into the tibial and common 
peroneal nerve and supplies both motor and sensory innervation to the posterior aspect of 
the lower extremity and foot.
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Figure 1. Brachial plexus anatomy.
Original illustration was created by Lieutenant Michael K. Sracic, MD, MC, US Navy for Military Advanced Regional 
Anesthesia and Analgesia Handbook@ 2008 The Henry M. Jackson Foundation for the Advancement of Military Medicine, 
Inc., and is reproduced with permission.
Technique
Fundamental to the success of peripheral nerve block is the correct positioning of the needle 
tip in proximity to the nerve, prior to injection of local anesthetic. This is accomplished by the 
use of ultrasound localization and/or nerve electrostimulation. Before the introduction of 
ultrasound, a nerve stimulator was used to identify proximity to the nerves and before that, 
needles were inserted using landmarks, inducing paresthesia or a facial ‘click’.
Low-level electrical current applied from the tip of a needle can elicit speci!c muscle 
contractions when the needle is in close proximity to a motor nerve. One lead of a low-output 
nerve stimulator is attached to a needle and the other lead is grounded elsewhere on the 
patient’s skin. After skin puncture, the stimulator is set to a frequency of 1 Hz and an initial 
current of 100 nC (1 mA x 0.1 ms). A pulse width of 0.1 ms is chosen because it is suf!cient for 
stimulation of motor !bers without stimulating sensory !bers, which may be uncomfortable 
for the patient. Muscle contractions occur and increase in intensity as the needle approaches 
the nerve and diminish when the needle moves away. Optimal positioning produces evoked 
Figure 3.  
Innervation of the lower extremity
Reproduced, with permission, from antranik.org.
Figure 2.  
Lumbosacral plexus anatomy
Original illustration was created by 
Lieutenant Michael K. Sracic, MD, MC, 
US Navy for Military Advanced Regional 
Anesthesia and Analgesia Handbook@ 
2008 The Henry M. Jackson Foundation 
for the Advancement of Military Medicine, 
Inc., and is reproduced with permission.
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contractions between 20 and 50 nC. Characteristically, the evoked response rapidly fades 
after injection of a few milliliters of local anesthetic. However, the sensitivity of nerve 
stimulation as a means of identifying proximity of the needle tip to the nerve is not 100%. 
Perlas et al.2 found that only 75% had a motor response at a current threshold less than 50 nC, 
despite visible needle-nerve contact during ultrasounds-guided axillary block. Nonetheless, 
electrostimulation is still considered a useful tool in conjunction with ultrasound, especially 
for con!rming nerve identity.3
The introduction of ultrasound has changed the practice of peripheral nerve block. 
Ultrasound offers the ability to visualize relevant anatomical structures, needle 
advancement, needle – nerve interaction, and local anesthetic spread in real time.4 Using 
ultrasound guidance, local anesthetic spread around the nerves can be visualized with the 
possibility of repositioning the needle in case of maldistribution,5 allowing for a reduction 
in local anesthetic dose without compromising the quality of the peripheral nerve block. 
Recent publications indeed illustrate that the volume of local anesthetic can be signi!cantly 
reduced when particular regional anesthetic techniques are performed with ultrasound 
guidance.6-9 This may in turn reduce the risk of local anesthetic systemic toxicity, and of 
unintentional blockade of other nerves in the vicinity.3
Sometimes extended duration of peripheral nerve block is desirable, f.e. when prolonged 
postoperative pain is expected, or to prevent the need for postoperative systemic analgesia. 
In that case, peripheral nerve block can be administered continuously using a catheter. A 
meta-analysis comparing continuous peripheral nerve block versus single shot peripheral 
nerve block shows that continuous peripheral nerve block offers superior pain control, less 
nausea, and higher patient satisfaction, with decreased opioid consumption during the 
initial postoperative period.10
Continuous peripheral nerve blocks provide superior pain relief for several days after painful 
surgical procedures; they facilitate early rehabilitation11,12 and may decrease adverse effects 
related to systemic analgesic medications.13,14 
For continuous peripheral nerve block, non-stimulating and stimulating catheters 
are available. Non-stimulating catheters are inserted blindly through the needle after 
obtaining a correct needle position as determined by nerve stimulation and/or ultrasound 
visualization. Stimulating catheters can be inserted while stimulating at the tip of the 
catheter. The expected added value of stimulation during insertion is that by maintaining an 
appropriate motor response, optimal positioning of the tip in close proximity of the nerve can 
be ensured.15
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Local anesthetics 
When performing a peripheral nerve block, the anesthesiologist must decide on the speci!c 
local anesthetic agent(s) as well as the volume, concentration and dose to be injected. The 
choice of local anesthetic in peripheral nerve block is mainly determined by the desired 
speed of onset, block intensity (potency), duration of anesthesia and analgesia and toxicity.16
Chemical structure
All local anesthetic molecules in clinical use have three parts: a lipophilic (aromatic) ring, a 
hydrophilic terminal amine, and an intermediate linkage between the aromatic ring and the 
terminal amine. The link contains either an aminoester or an aminoamide bond, and local 
anesthetics are designated as belonging to one of two groups: aminoesters or aminoamides. 
All drugs known and used as local anesthetics have originated form cocaine, the alkaloid 
found in the leaves of the South American bush Erythroxylon coca. Its local anesthetic action 
was !rst demonstrated in 1884 by Koller, a resident with an interest in ophthalmology in 
the General Hospital in Vienna.17 That same year, the American surgeons Halsted and Hall 
performed the !rst sensory nerve blocks by injecting cocaine into peripheral sites.18 The drug 
lost its popularity because of its systemic toxicity, central nervous stimulant and addictive 
properties and tendency to produce allergic reactions. Fundamental to the development of 
safer synthetic local anesthetics was the demonstration of the physical structure of cocaine 
as an ester of benzoic acid.19 Procaine, one of the !rst synthetic local anesthetics, was 
synthesized by the German chemist Einhorn in 1905.20 Concerning the local anesthetics used 
in this thesis, mepivacaine was !rst mentioned in the literature in 195621 and the !rst trials 
with ropivacaine followed much later in 1983.22
Mechanism of action
Local anesthetics act by reversibly blocking voltage-gated sodium channels in axons in all 
excitable tissues. When stimulated, a depolarization in an axon membrane opens the voltage 
gated sodium channels. Blockade of these channels prevents sodium (Na+) movement 
through the sodium channel and interrupts membrane depolarization and thus blocks nerve 
conduction.23
Absorption, distribution and metabolism
The changes in plasma concentration of drug following injection are dependent on the total 
dose administered, the rate of absorption, the pattern of distribution to other tissues, and 
the rate of metabolism. Vascularity and the presence of tissue and fat capable of binding 
local anesthetics will be the main determinants of the rate of removal of the drug frorm the 
site of injection.23 Absorption from the site of injection depends on the blood "ow; the higher 
the blood "ow, the more rapid is the increase in plasma concentration. Blood "ow may be 
modi!ed by vasoactive properties of the drug itself or by the addition of vasocontrictors such 
as epinephrine to the solution.24 
After absorption, local anesthetics are distributed rapidly to, and taken up by, organs with 
a large blood supply and high af!nity, e.g. brain, heart, liver and lungs. Local anesthetic 
drugs are sequestered in (and possibly metabolized in) the lungs, thereby preventing a 
large proportion of the injected dose from reaching the coronary and cerebral circulations. 
Eventually, tissue concentration of local anesthetic decreases below that in the nerve !bers 
and the drug diffuses out, so allowing restoration of normal nerve function.25 
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Ester drugs are broken down by plasma cholinesterase (hydrolyzed by esterases in tissues 
and blood). The amides are metabolized by amidases (microsomal P-450 enzymes) located 
predominantly in the liver.25 
Differences in the clinical pro!les of individual agents (onset, potency, duration of action, 
etc) are related to variations in the physiochemical properties. The important factors are the 
pKa (onset), lipid solubility (potency and duration of action) and degree of binding to protein 
(toxicity).
Clinical pro!les
Speed of onset – pKa
Local anesthetics are weak bases. There is a balance between uncharged (free base, LA) and 
positively charged (cation, LAH+) forms present in the body. The ratio of cation to free base 
is determined by the pKa of the local anesthetic and the pH of the solution. The pKa is the 
pH at which 50% of the drug is ionized and 50% is present as base.25 Increasing the pH of a 
solution increases the ratio of free base to cation. Commercial solutions of local anesthetics 
are usually injected in an acid solution as the hydrochloride salt (pH approximately 5), so the 
hydrophilic (cationic, LAH+) state is favored. After injection, the pH increases as a result of 
buffering in the tissues and a proportion of the drug dissociates to release free base.25 The 
uncharged free base is more lipophilic and thus more rapidly diffuses through the membrane 
to the interior of the axon, where re-ionization takes place. The charged form has a higher 
af!nity for the receptor site of the sodium channel and it is this re-ionized portion that enters 
and blocks the sodium channels (Figure 4). As a result, no action potential is generated or 
transmitted, and conduction blockade occurs. A low pKa favors rapid onset of action because 
more of the drug is uncharged at physiological pH and is thus lipid permeant.25
Figure 4. Local anesthetic interaction with sodium channel
Potency and duration of action – Lipid solubility and vasoconstriction
Duration of action is related to the extent to which local anesthetic remains in the vicinity of 
the nerve. This is determined largely by three factors; lipid solubility the degree of vascularity 
of the tissue and the presence of vasocontrictors that prevent vascular uptake. The more 
lipid soluble the drug, the more likely it will remain in the lipid-rich environment of the 
axonal membrane. There is a positive correlation between lipid solubility of local anesthetics 
and intrinsic local anesthetic potency.23 Chemical compounds which are highly lipophilic 
tend to penetrate the nerve membrane more easily, so that less molecules are required for 
conduction blockade. They are more potent and produce longer acting blockade than less 
lipophilic agents.26
More lipophilic agents are attracted to plasma proteins to a greater extent than less 
lipophilic agents. 
Therefore, there is a direct correlation between protein binding and lipid solubility. This 
means that duration of action relates to the degree of protein binding with a longer duration 
of action in drugs with a higher fraction of protein binding.23
Block duration is further determined by the degree of vascularity of the tissue and the 
presence of vasoconstrictors that prevent vascular uptake. This varies signi!cantly 
among individual nerve blocks and different types of local anesthetics. The addition of a 
vasoconstrictor to a local anesthetic delays its vascular absorption, increasing the duration 
of drug being in vicinity of nerve tissues. Also, intrinsic vasoactive properties relate to 
duration of action. The vasoconstriction at low concentrations of ropivacaine is likely to 
contribute to its long duration of action.27 
Toxicity - Protein binding
Local anesthetics are in large part bound to plasma and tissue proteins. However, they are 
pharmacologically active only in the free unbound state. The main plasma proteins involved 
in drug binding are albumin, α1-acid glycoprotein (AAG) and the lipoproteins, with AAG being 
primarily responsible for the binding of basic drugs, such as local anesthetics.23 Plasma 
concentrations of AAG are increased as a result of various pathophysiological conditions, 
such as surgery, trauma and certain disease states, with a subsequent rise in plasma protein 
binding.28
Local anesthetics are bound to plasma proteins to varying degrees. Drugs with the greatest 
degrees of protein binding have the smallest fraction of the total amount in plasma free 
to diffuse into other tissues and possibly produce toxic effects. Toxicity of local anesthetics 
is mostly related to their inhibitory effects on other excitable cells in the central nervous 
and cardiovascular system.24 Following absorption, local anesthetics cause stimulation 
of the central nervous system, such as auditory changes, circumoral numbness, metallic 
taste, and agitation. Stimulation is caused by inhibition of inhibitor neuronal activity of 
the higher cortical centers. At high blood concentrations, local anesthetics cause central 
nervous system depression and even respiratory failure. In the cardiovascular system, local 
anesthetics cause cardiac excitation (hypertension, tachycardia, ventricular arrhythmias). 
With greatly increased blood concentrations, cardiac excitation may be followed by cardiac 
depression (bradycardia, asystole, decreased contractility, and hypotension).29
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Duration of peripheral nerve blocks: Focus and outline of the thesis
Duration of peripheral nerve block depends on several factors such as the choice of local 
anesthetic, the presence of adjuncts such as epinephrine or clonidine, and the use of a 
catheter for prolonged infusion. Choices can be made dependent on the purpose of the nerve 
block; is it for intraoperative anesthesia and/or should it provide (prolonged) postoperative 
analgesia.
Intraoperative anesthesia for minimally painful surgery: short acting local anesthetics
If the goal is to provide surgical anesthesia for minimally painful surgery, a short acting 
local anesthetic can be used. From a safety perspective a lower dose is preferable and using 
ultrasound guidance, adequate peripheral nerve block can be established with a lower 
volume. In Chapter 2 we evaluated the effect of the volume of mepivacaine 1.5% on the 
duration of sensory and motor block in ultrasound-guided axillary brachial plexus block. 
We designed the study in Chapter 3 to determine if a similar dose administered in different 
volumes and concentrations would affect the duration of sensory and motor block in axillary 
brachial plexus block, as well as if different doses administered in a similar volume would 
have any effect.
Intraoperative anesthesia and postoperative analgesia: long acting local anesthetics with 
additives
For surgery where some postoperative pain is expected, a longer acting local anesthetic 
can be used. This can provide surgical anesthesia and cover the !rst postoperative hours 
in terms of postoperative analgesia. To optimize safety, epinephrine can be added to large 
doses of ropivacaine in order to reduce the maximum concentration or to act as a marker 
for intravascular injection. In Chapter 4 we describe the pharmacokinetic pro!le in serum 
of 450 mg ropivacaine with and without epinephrine, in patients undergoing anterior 
cruciate ligament reconstruction under single-shot combined sciatic/femoral nerve block. 
The purpose of Chapter 5 is to compare the duration of postoperative analgesia of 30 mL 
ropivacaine 0.75% with or without epinephrine for popliteal sciatic nerve block. In this study 
a nerve catheter is inserted to provide prolonged postoperative analgesia.
Postoperative prolonged action with a perineural catheter
If postoperative pain is expected to be severe and longer lasting, e.g. in arthroplasty, a nerve 
catheter can be inserted for prolonged infusion of local anesthetic. For continuous nerve 
block, stimulating and non-stimulating catheters can be used. In Chapter 6 we investigated 
whether there is a correlation between the minimal electrical charge at the tip of a blindly 
inserted stimulating catheter necessary to elicit an appropriate motor response, and the 
ef!cacy of the peripheral nerve block catheter as determined by postoperative PCA morphine 
consumption. 
Chapter 7 of this thesis summarizes and discusses our main !ndings in relation to the 
current literature and gives recommendations for future research.
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Chapter 02
Effect of local anesthetic 
volume (15 vs 40 mL) on the 
duration of ultrasound-guided 
single shot axillary brachial 
plexus block: 
a prospective randomized 
observer-blinded trial
Schoenmakers K.P.W., Wegener J.T., Stienstra R.
Regional Anesthesia and Pain Medicine. 2012 May-Jun; 37(3):242-247
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Abstract
Background: One of the advantages of ultrasound-guided peripheral nerve block is that 
visualization of local anesthetic spread allows for a reduction in dose. However, little is 
known about the effect of dose reduction on sensory and motor block duration. The purpose 
of the present study was to compare the duration of sensory and motor axillary brachial 
plexus block with 15 or 40 mL mepivacaine 1.5%.
Methods: Thirty patients were randomly allocated to receive ultrasound-guided axillary 
brachial plexus block with either 15 (group 15 mL, n = 15) or 40 mL (group 40 mL, n = 15) 
mepivacaine 1.5%. Onset, ef!cacy and duration of sensory and motor block were compared.
Results: Two patients in group 15 mL needed an additional rescue block before surgery and 
were excluded from subsequent analysis. The median overall duration of sensory and motor 
block was signi!cantly shorter in group 15 mL (225 [148-265] mins vs 271[210-401] mins and 
217 [144-250] mins vs 269 [210-401] mins respectively, P < 0.01). Duration of sensory and motor 
block of individual nerves was signi!cantly shorter in group 15 mL (20%-40% reduction for 
sensory and 18%-37% for motor block). Time to !rst request of postoperative analgesia was 
also signi!cantly reduced in group 15 mL (163 [SD, 39] versus 235 [SD, 59] mins, respectively,  
P < 0.05). There were no differences in the other block characteristics. 
 
Conclusions: In ABPB with mepivacaine 1.5%, reducing the dose from 40 mL to 15 mL (62.5%) 
shortens the overall duration of sensory and motor block by approximately 17%-19%, reduces 
sensory and motor block duration of individual nerves by 18% to 40%, and decreases the 
time to !rst request of postoperative analgesia by approximately 30%.
LA volume and duration of US-guided ABPB
Introduction
Peripheral nerve block as an anesthetic technique plays an important role in modern 
regional anesthesia. The most important prerequisites for the use of peripheral regional 
anesthesia in daily clinical practice are success rate and safety. Ultrasound guidance 
shortens block performance time, reduces the number of needle insertions, and shortens the 
block onset time.1 Recent publications illustrate that the volume of local anesthetic can be 
signi!cantly reduced with the use of ultrasound.2-10
Axillary brachial plexus block (ABPB) is widely used to provide anesthesia for surgery of the 
forearm, wrist, and hand. The procedure is relatively safe and complications are uncommon.11 
Before the introduction of ultrasound, volumes of 40 mL or even more were commonly 
used.12 Recent research has focused on reducing the volume necessary to establish adequate 
ABPB. Volumes of 5 mL per nerve13 or even as low as 1 mL lidocaine 2% per nerve8 have been 
reported to achieve successful ABPB. However, the effect of dose reduction on block duration 
remains unknown.  
The purpose of the present study was to evaluate the effect of the volume of mepivacaine 
1.5% on the duration of sensory and motor block in ultrasound-guided ABPB.  
Materials and Methods
Patients
This prospective single-blinded, randomized study was approved by the Institutional Review 
Board Nijmegen and registered at http://www.trialregister.nl (NTR2371) before participant 
enrollment. Patients scheduled for a single shot ABPB for hand, wrist, or forearm surgery 
were assessed for eligibility during the preoperative screening visit. Patients were informed 
about the study verbally and in writing, and written informed consent was obtained from all 
patients. The study was conducted at the Sint Maartenskliniek, Nijmegen, the Netherlands, 
between July 2010 and March 2011 in accordance with the Declaration of Helsinki and later 
revisions thereof, as well as ICH guidelines for Good Clinical Practice.
Eligible participants were adults 18 years or older with American Society of Anesthesiologists 
physical health classi!cation I-III and a body weight greater than 50 kg. Exclusion 
criteria included contraindications for regional anesthesia (infection at the injection site, 
coagulopathy), known hypersensitivity to amide-type local anesthetics, known history of 
peripheral neuropathy, and known history of hepatic or renal insuf!ciency.
Anesthetic procedure
All patients received paracetamol 1000 mg orally 3 times daily and meloxicam 15 mg orally 
once daily, starting on the morning of surgery. Additional postoperative pain treatment was 
provided upon patient request and consisted of oxycodone 10 mg orally 4 to 6 times daily.
Using a computer-generated sequence of random numbers and a sealed envelope technique, 
30 patients were randomly allocated to receive ultrasound-guided ABPB with either 15 
(group 15 mL, n = 15) or 40 mL (group 40 mL, n = 15) mepivacaine 1.5%. After establishing 
intravenous access and routine monitoring (electrocardiogram, noninvasive blood pressure, 
and peripheral oxygen saturation), ABPB was performed under ultrasound guidance (L12-5 
linear probe connected to Philips HD11 XE; Philips, Eindhoven, the Netherlands) using a 
short axis, in-plane technique. Blocks were performed under aseptic conditions using 
chlorhexidine skin preparation and sterile ultrasound probe covers (Flexasoft; Medicocare, 
Numansdorp, the Netherlands). 
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A 100-mm, 22-gauge, insulated short-bevel needle (Stimuplex B. Braun, Melsungen, 
Germany) was inserted laterally in the axilla. The needle was connected to a nerve stimulator 
(Stimuplex HNS 11; B. Braun) that was set to deliver 100 nC (0.1 millisecond, 1 mA), only to 
facilitate identi!cation of the individual nerves. After identifying the musculocutaneous, 
median, ulnar, and radial nerves, each nerve was blocked with either 10 mL (40 mL group) or 3 
to 4 mL (15 mL group) mepivacaine 1.5%. 
Time was designated t = 0 upon conclusion of the block procedure. 
Clinical assessments
In the !rst 30 mins after injection of the local anesthetic solution, a blinded observer assessed 
the onset of sensory and motor block every 5 mins. Sensory block of the medial antebrachial 
cutaneous, musculocutaneous, radial, median, and ulnar nerves was assessed by pinprick at 
speci!c sites (Table 1). Sensory block was scored on a 3-point scale as 0 = absent, 1 = partial, 
and 2 = complete. At the same intervals, motor block of the musculocutaneous, radial, 
median, and ulnar nerves was assessed (Table 1) on a similar 3-point scale (0 = no, 1 = partial, 
and 2 = complete motor block). A complete overall sensory block was de!ned as a total score 
of 10; complete overall motor block was de!ned as a total score of 8. In case of insuf!cient 
analgesia at the surgical site at t = 30 mins, an additional rescue block was placed in the block 
room, and the patient was excluded from further analysis.
Table 1. Sensory and Motor Testing
Nerve Sensory test site Motor test
Medial antebrachial cutaneous Medial side forearm -
Musculocutaneous Lateral side forearm Elbow "exion
Radial Dorsum of hand Wrist extension 
Median Ventral top of middle !nger Thumb opposition
Ulnar Hypothenar eminence Finger abduction
Surgery was performed under regional anesthesia. In the case of patient discomfort or 
upon patient request, sedation was provided with propofol (25-60 µg/kg per minute) and 
remifentanil (0.01-0.05 µg/kg per minute). If sedation was insuf!cient in case for patient 
discomfort, patients were converted to general anesthesia.
Upon arrival at the recovery room, offset of sensory and motor block was assessed by a 
blinded observer every 15 mins in the same manner as preoperatively until full recovery. 
The primary outcome parameter was overall duration of sensory block. Overall duration of 
sensory block was de!ned as the time from t = 0 until the !rst postoperative measurement 
where total sensory score had returned to 0. Overall duration of motor block was de!ned 
similarly. Duration of sensory and motor block of individual nerves was de!ned as the time 
from t = 0 until the !rst postoperative measurement where the sensory and motor score 
for the individual nerve was 0. Secondary outcome parameters included overall duration 
of motor block, duration of sensory and motor block of individual nerves, block onset time, 
block ef!cacy and time to !rst request for additional postoperative pain treatment (TTFR). 
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Block onset time was de!ned as the time from t = 0 until the time sensory, respectively, 
motor score was maximal. Block ef!cacy during surgery was assessed as successful (no 
intraoperative sedation necessary), partially successful (intraoperative sedation necessary), 
or unsuccessful (conversion to general anesthesia). Time to !rst request for additional 
postoperative pain treatment was de!ned as the time interval from t = 0 until the time the 
!rst request for postoperative analgesia was made.
Sample size and statistical analysis
The sample size calculation was based on the overall duration of sensory block. Robaux et 
al.14 found a sensory duration of ABPB (with 40 mL mepivacaine 1.5%) of 183 (SD, 43) mins. 
Based on these data, the sample size required to have a 90% probability of detecting a 
decrease in duration of 60 min (level of signi!cance 0.05) was 12 patients per group using an 
unpaired t test. Compensating for dropout, we chose to include 15 patients per group.
Analysis was per protocol. Data were analyzed using the GraphPad InStat v. 3.10 package 
(GraphPad Software Inc, San Diego, California). The Kolmogorov-Smirnov test was used for 
normality testing. Continuous, normally distributed data were presented as mean (SD), and 
non-normally distributed data as median (range). Statistical comparison between the groups 
was based on the Student t test for normally distributed data, and the Mann-Whitney U test 
for nonparametric comparisons. For comparisons within groups, normally distributed data 
were compared using the 1-way analysis of variance, and non-normally distributed data 
using the Kruskal-Wallis test. Post hoc comparisons were made using Tukey-Kramer or Dunn 
multiple comparisons test as appropriate. Categorical data were compared using Fisher 
exact test. In case where a parameter was normally distributed in 1 group and nonnormally 
in the other group, the data are presented as median (range) and a nonparametric test 
was used for statistical comparison. All tests were 2-sided, and P < 0.05 was considered 
statistically signi!cant.
Patients assessed for eligibility
(n = 75)
Excluded (n = 45)
- Not eligible (n = 5)
- Did not provide consent (n = 26)
- Logistic reasons (14)
Randomized
(n = 30)
Allocated to group 15 ml (n = 15)
Received allocated intervention (n = 15)
Allocated to group 40 ml (n = 15)
Received allocated intervention (n = 15)
Analyzed (n = 13)
Excluded from analysis due to 
receiving rescue block (n = 2)
Analyzed (n = 15)
Excluded from analysis (n = 0)
Figure 1. Flowchart of patients enrolled in the study.
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Results
Thirty patients were included, 15 in each group. A flowchart of patients enrolled in this study 
is presented in Figure 1. In group 15 mL, 2 patients needed a rescue block before surgery 
because of incomplete block in the surgical area, compared with 0 patients in group 40 
mL. These 2 patients were excluded from subsequent analysis. There were no significant 
differences in patient demographics between the 2 groups (Table 2). 
Table 2. Baseline Characteristics
Group 15 mL (n=13) Group 40 mL (n=15)
Sex, no. male/no. female 5/8 4/11
Age, y 53 (16) 55 (9)
Height, cm 171 (9) 173 (8)
Weight, kg 76 (13) 78 (14)
Body mass index, kg/m2 25.8 (3.7) 25.8 (2.8)
Duration of surgery, min 23.2 (15.6) 21.5 (10.7)
Group 15 mL: axillary brachial plexus block with 15 mL mepivacaine 1.5%. Group 40 mL: axillary brachial 
plexus block with 40 mL mepivacaine 1.5%. Values are numbers or mean (SD). 
On 7 time points postoperatively, we were unable to obtain a measurement of sensory and 
motor blocks in 6 patients because of temporary patient unavailability. In 5 patients, these 
missing data did not affect the outcome parameters because sensory and motor blocks were 
still present at the next measurement. In 1 patient (group 40 mL), we missed 2 consecutive 
measurements during which both sensory and motor blocks had completely resolved. In this 
patient, we took the !rst time point following the missing data to calculate overall block 
duration; replacing this time point with the !rst time point where we were unable to obtain 
a measurement (30 mins earlier) revealed that this did not signi!cantly affect the results.  
Block characteristics
Thirty minutes after block placement 7 of 13 patients in group 15 mL had a complete 
sensory block (maximum score of 10) versus 9 of 15 patients in group 40 mL (not statistically 
signi!cant [NS]). Onset of complete sensory block was 21 (SD, 5) mins in group 15 mL  
(n = 7) and 22 (SD, 6) mins in group 40 mL (n = 9) (NS). After 30 mins, motor block was complete 
(maximum score of 8) in 8 of 13 patients in group 15 mL versus 11 of 15 patients in group 40 mL 
(NS). Onset of complete motor block was 22 (SD, 8) mins and 23 (SD, 7) mins in group 15 mL  
(n = 8) and group 40 mL (n = 11), respectively (NS). There were no signi!cant differences 
between the groups in the onset times of sensory/motor block of individual nerves. Data on 
sensory and motor block scores of individual nerves are shown in Table 3.
Table 3. Block Scores of Individual Nerves at 30 mins
Nerve Group 15 mL (n = 13) Group 40 mL (n = 15)
Score 2 Score 1 Score 0 Score 2 Score 1 Score 0
Med. anteb. cut. sens  11 2 - 14 1 -
Musculocutaneous sens 12 1 - 12 3 -
Musculocutaneous mot 9 4 - 13 2 -
Radial sens 10 3 - 12 3 -
Radial mot 11 2 - 11 4 -
Median sens 11 2 - 14 1 -
Median mot 11 2 - 15 - -
Ulnar sens 11 2 - 15 - -
Ulnar mot 11 2 - 14 1 -
Groups as de!ned in Table 2. Values are numbers. Med. anteb. cut. indicates medial antebrachial 
cutaneous nerve; sens, sensory block score; mot, motor block score. 
The median overall duration of sensory block in group 40 mL was 271 (range, 210-401) mins 
versus 225 (range, 148-265) min in group 15 mL (P < 0.001). The median overall duration of 
motor block was 269 (range, 210-401) mins in group 40 mL versus 217 (range, 144-250) mins in 
group 15 mL (P < 0.001). Overall duration was largely determined by the duration of sensory 
and motor block of the ulnar nerve. In 10 of 13 patients in group 15 mL and 10 of 15 patients 
in group 40 mL, the ulnar nerve was among the last to recover. Within each group, there 
were no signi!cant differences in the duration of sensory and motor block between the 
individual nerves. Between groups, the duration of both sensory and motor blocks for each 
individual nerve was signi!cantly longer in group 40 mL. Data on overall and individual block 
characteristics are summarized in Table 4 and Figures 2-4.
Twelve patients, 6 in each group, requested additional postoperative analgesia. Time to !rst 
request for additional postoperative pain treatment was signi!cantly shorter in group 15 
mL (163 [SD, 39] mins) as compared to group 40 mL (235 [SD, 59] mins) (P < 0.05). Twenty-!ve 
patients underwent surgery without need for additional sedation. Three patients, 2 in group 
15 mL and 1 patient in group 40 mL, needed sedation because of patient discomfort. None of 
the patients required conversion to general anesthesia.
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Table 4. Sensory and Motor Block Duration of Individual Nerves
Group 15 mL
(n = 13) 
Group 40 mL
(n = 15)
P Difference,* 
%
Overall sensory block duration 225 (148-265) 271 (210-401) <0.001 17
Overall motor block duration 217 (144-250) 269 (210-401) <0.001 19
Med. anteb. cut. nerve
   Sensory block, min 157 (98-235) 262 (191-301) < 0.0001 40
Musculocutaneous nerve
   Sensory block, min
   Motor block, min
154 (68-235)
160 (114-233)
247 (151-296)
254 (150-311)
< 0.01
< 0.0001
38
37
Radial nerve
   Sensory block, min
   Motor block, min
173 (103-235)
190 (114-225)
235 (177-401)
262 (150-351)
< 0.001
< 0.001
26
27
Median nerve
   Sensory block, min
   Motor block, min
184 (133-265)
173 (129-235)
241 (192-349)
245 (207-301)
< 0.001
< 0.001
24
29
Ulnar nerve
   Sensory block, min
   Motor block, min
202 (148-250)
210 (144-250)
252 (210-351)
256 (210-401)
< 0.001
< 0.001
20
18
Groups as de!ned in Table 2. Values are median (range). *Difference, difference between the medians of 
group 40 mL and group 15 mL as a percentage of the median value of group 40 mL. Med. anteb. aut. nerve 
indicates medial antebrachial cutaneous nerve. 
Figure 3. Duration of sensory block of individual nerves in group 15 mL (A) and group 40 mL (B).
Dots are individual data; horizontal bars represent median values. Med. anteb. cut. indicates medial antebrachial 
cutaneous nerve.
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Figure 2. Duration of overall sensory (A) and motor (B) block.
Dots are individual data, horizontal bars represent median values.
Figure 4. Duration of motor block of individual nerves in group 15 mL (A) and group 40 mL (B).
Dots are individual data; horizontal bars represent median values.
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Discussion
In the present investigation, a local anesthetic volume reduction of 60% resulted in an 
approximately 17% shorter overall sensory and 19% motor block duration and a reduction 
in TTFR of approximately 30%. Because overall duration is determined by the last nerve to 
recover, this parameter may underestimate the effect of a reduction in dose. Indeed, we 
found that the reduction in duration for individual nerves was larger, varying from 20% 
to 40% for sensory block and from 18% to 37% for motor block. The ulnar nerve was least 
affected by the reduction in dose; the 2 nerves most strongly affected were the medial 
antebrachial cutaneous and musculocutaneous nerves. 
Duration of peripheral nerve block depends on several factors, such as the choice of local 
anesthetic, the site of injection and the presence of adjuncts, for example clonidine or 
epinephrine. Some studies in children implicate that the use of ultrasound guidance itself 
provides a longer duration of sensory blockade compared with nerve stimulation without 
ultrasound.15,16 The dose of local anesthetic administered when performing peripheral 
nerve block is determined by volume and concentration; the manner in which these 
parameters affect duration is controversial. In a study aimed to determine the minimum 
effective anesthetic volume for blocking the median and ulnar nerve with mepivacaine 
1.5%, Ponrouch et al17 found that the use of ultrasound as compared with nerve stimulation 
reduced the effective anesthetic volume by 50%. They also found a signi!cant correlation 
between the volume of local anesthetic and the duration of sensory blockade, the correlation 
being higher with lower volumes. Similar !ndings were reported in a volunteer study 
designed to determine the ED99 volume of mepivacaine 1.5% for sciatic nerve block, showing 
a proportional relation between volume of local anesthetic per millimeter squared cross-
sectional nerve area and duration of sensory block.18 In a study comparing low-volume  
(16 mL) ultrasound-guided ankle block with a conventional higher-volume (30 mL) landmark 
technique using ropivacaine 0.5%, Fredrickson et al19 found that average postoperative pain 
was marginally higher in the low-volume group. Although the authors did not measure block 
duration or the time to !rst request of postoperative analgesia directly, the results suggest a 
shorter duration of sensory block associated with the low-volume group.  
On the other hand, Serradell et al20 compared the number of complete sensory blocks for 
different volumes (20, 28, 36 mL) of mepivacaine 1% in axillary block and found no differences 
in success rate, onset time, and duration of analgesia among the 3 groups. The results of 
the latter study suggest that 200 mg mepivacaine in a volume of 20 mL provides adequate 
axillary block and that increasing the volume/dose of mepivacaine to 280 or 360 mg does 
not result in a higher success rate or a longer duration of analgesia. Duration of analgesia 
reported by Serradell et al20 was 231 (SD, 45) mins in their group receiving axillary block 
with 200 mg mepivacaine in 20 mL. Interestingly, the TTFR in our group 40 mL (600 mg 
mepivacaine) was similar (235 [SD, 59] mins), whereas the TTFR in our group 15 mL (225 mg 
mepivacaine) was considerably shorter. Although differences in methodology preclude 
making direct comparisons, these observations may indicate that the reduction in block 
duration seen in our study is caused by the reduction in volume from 40 mL to 15 mL rather 
than the reduction in dose from 600 mg to 225 mg. However, further study is required to 
substantiate this. The data from our study are in accordance with the studies reporting a 
correlation between volume of local anesthetic and duration of peripheral nerve block. 
The possibility of reducing the volume (and dose) of local anesthetic with ultrasound-
guided peripheral nerve block is an obvious advantage from a safety perspective. Short- to 
intermediate-acting local anesthetics, such as mepivacaine, are used for surgeries where 
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postoperative pain is expected to be moderate and/or short lived. Block duration should 
cover surgery and the immediate period afterward, but prolonged analgesia postoperatively 
is not indispensable, and a reduction in block duration caused by reduced volume has little 
clinical relevance if surgery can be concluded before the block starts to wear off. Whether the 
pharmacodynamic !ndings regarding volume of mepivacaine equally apply for other local 
anesthetics, such as ropivacaine or levobupivacaine, remains to be determined. In situations 
where a long-acting local anesthetic is preferred, a shorter duration of sensory block may 
be an unfavorable trade-off when the intention is to obtain long-lasting postoperative 
analgesia. In those circumstances, the advantage of a dose reduction must be balanced 
against the possibility of a shorter duration of postoperative analgesia. In cases where 
prolonged postoperative analgesia is desirable, the use of a perineural catheter technique 
should be considered. Determining the lowest volume without decreasing duration of 
sensory block requires further study.
A limitation of our study is that we did not determine whether intraneural spread was 
present; although we tried to avoid intraneural injection, we cannot exclude the possibility 
that this may have occurred with individual nerves, which may have prolonged block 
duration. 
In conclusion, reducing the volume of mepivacaine 1.5% for ABPB from 40 mL to 15 mL 
resulted in a reduction of overall block duration of approximately 17% to 19%, a reduction 
of block duration in individual nerves ranging from 18% to 40%, and a reduction in TTFR of 
approximately 30%. 
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Effect of local anesthetic 
concentration, dose and volume 
on the duration of single-
injection ultrasound-guided 
axillary brachial plexus block 
with mepivacaine: 
a randomized controlled trial
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Abstract
Background: In what way volume, concentration and dose affect block duration is 
controversial. The purpose of the present study is to study the effect of dose, volume and 
concentration of mepivacaine on the duration of sensory and motor blockade in ultrasound-
guided single shot axillary brachial plexus blockade.
Methods: In this parallel group randomized trial conducted in the Sint Maartenskliniek 
Nijmegen, 45 adult patients undergoing minor orthopaedic forearm, wrist or hand surgery 
were randomized to 3 groups. Group A: 20 mL mepivacaine 1.5%, Group B: 30 mL mepivacaine 
1% and Group C: 30 mL mepivacaine 1.5%. Randomization was computer-generated, with 
allocation concealment by opaque sequentially numbered sealed envelopes. Patients and 
observers were blinded to group allocation. Primary outcome measure: duration of sensory 
block.  
Results: Forty-!ve patients were randomized, four patients were excluded and replaced,  
and 15 patients in each group were included in the analysis. Mean (95% CI) sensory and 
motor block duration was 256 (230-282) and 254 (226-282) minutes in Group A, 226 (209-
243) and 220 (200-240) minutes in Group B and 270 (249-291) and 264 (244-284) minutes 
in Group C. Duration of sensory and motor block duration differed signi!cantly between 
groups (p=0.012 and p=0.016 respectively). Post-hoc analysis showed a signi!cantly reduced 
sensory and motor block duration in Group B when compared to Group C of 44 min. No local 
anesthetic systematic toxity was reported.   
Conclusions: When using equal volumes of mepivacaine for axillary brachial plexus block,  
a higher dose and concentration was associated with a longer duration of sensory and motor 
blockade, but not a higher volume.  
Conc, dose & vol of LA and duration of ABPB
Introduction
The introduction of ultrasound has changed the practice of peripheral nerve block (PNB). 
Using ultrasound guidance, local anesthetic (LA) spread around the nerves can be assessed 
with the possibility of repositioning the needle in case of maldistribution,1 allowing for a 
reduction in LA dose without compromising the quality of PNB. Recent publications indeed 
illustrate that the volume of LA can be signi!cantly reduced when particular regional 
anesthetic techniques are performed with ultrasound guidance.2-5 While dose reduction is 
advantageous from a safety perspective, an unwanted tradeoff may be a shorter duration of 
the nerve blockade.
One of the factors affecting the duration of peripheral nerve block is the dose of LA, dose 
being the product of volume and concentration. In what way volume, concentration and 
dose of LA affect block duration is subject to debate.6 In a recent study, we compared the 
duration of sensory and motor block of 15 and 40 mL mepivacaine 1.5% for axillary brachial 
plexus blockade (ABPB) using ultrasound guidance.7 Volume reduction from 40 mL to 15 mL 
(62.5%) shortened the overall duration of sensory and motor block by approximately 17-19%, 
reduced sensory and motor block duration of individual nerves with 18-40% and decreased 
the time to !rst request of postoperative analgesia by approximately 30%. The difference in 
block duration observed in this study was the effect of either a reduction in volume from 40 
to 15 mL or a reduction in dose from 600 to 225 mg or a combination. We designed the present 
study to determine if the reduction in duration of sensory and motor blockade in A is mainly 
affected by volume reduction or by dose reduction of mepivacaine. The null hypothesis was 
that sensory block duration is not affected by dose and volume reduction.
Materials and Methods
This study was set up as a Phase IV, monocenter, double-blinded (for observer and patient), 
parallel group randomized (1:1:1) trial. No protocol amendments were made during the study 
conduct. The study was approved by the Independent Review Board Nijmegen and was 
registered with the Nederlands Trial Register (www.trialregister.nl, number NTR3648) before 
onset of participant enrollment.
Eligible patients were all adults aged 18 or over with ASA physical health classi!cation 
I-III, scheduled for single-injection ABPB for hand, wrist or forearm surgery. Exclusion 
criteria included contra-indications for regional anesthesia (infection at the injection site, 
coagulopathy), known hypersensitivity to amide-type local anesthetics, and known history 
of peripheral neuropathy. Speci!c criteria for withdrawal and replacement included: failure 
to perform adequate single-injection ABPB and failure to complete the study protocol. 
Patients were assessed for eligibility during the preoperative screening visit. Patients were 
informed about the study verbally and in writing and written informed consent was obtained 
from all patients. 
The study was conducted at the Sint Maartenskliniek Nijmegen, The Netherlands between 
October 2012 and June 2014 according to the Declaration of Helsinki and later revisions 
thereof and in accordance with the ICH guidelines for Good Clinical Practice.  
The Sint Maartenskliniek specializes in posture and movement. The orthopedic center 
is facilitated by an anesthesiology department specialized in locoregional and regional 
anesthesia techniques.
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Study procedure
Study medication was prepared by an anesthetic nurse not involved in the study and 
was disclosed to the anesthesiologist performing the block procedure. Study medication 
consisted of either 20 mL mepivacaine 1.5%; 300 mg (Group A), 30 mL mepivacaine 1.0%;  
300 mg (Group B), or 30 mL mepivacaine 1.5%; 450 mg (Group C). 
After establishing intravenous access and routine monitoring (ECG, non-invasive blood 
pressure and peripheral oxygen saturation), ABPB was performed under ultrasound 
guidance using a short axis, in-plane technique. All blocks were placed by experienced 
anesthesiologists with the assistance of an anesthetic nurse. Blocks were performed under 
aseptic conditions using chlorexidine skin preparation and sterile ultrasound probe covers. 
The patient was placed in supine position with the head facing away from the arm to be 
blocked, the arm abducted and the elbow "exed in 90°. A 100-mm 22-gauge insulated short 
bevel needle (Stimuplex®; B. Braun, Melsungen, Germany) was inserted laterally in the 
axilla under ultrasound guidance. The musculocutaneous, median, ulnar and radial nerve 
were identi!ed using ultrasound and the tip of the needle was brought in proximity of each 
individual nerve subsequently. The needle was connected to a nerve stimulator (Stimuplex® 
HNS 11; B. Braun) set to deliver 100 nC (0.1 ms, 1 mA) in order to facilitate identi!cation of 
the individual nerves. The nerves were identi!ed and blocked separately with one fourth of 
the study medication per nerve. Per patient one skin puncture was made, the needle was 
retracted subcutaneously and redirected under ultrasound guidance to approach the nerves 
individually. Time was designated t = 0 upon conclusion of the block procedure. 
In case of insuf!cient analgesia at the surgical site at t = 30 min, an additional rescue block 
was placed in the block room, or surgery was performed under general anesthesia. These 
patients were excluded from further analysis and replaced.
Surgery was performed under regional anesthesia. In case of patient discomfort or upon 
patient request, sedation was provided with propofol (25–60 µg.kg-1.min-1) and remifentanil 
(0.01–0.04 µg.kg-1.min-1). 
The patients received paracetamol 1g orally four times daily and etoricoxib 90 mg orally 
once a day, starting on the morning of surgery. When the block started to wear off, additional 
postoperative pain treatment consisted of morphine 0.1-0.15 mg/kg every 4h subcutaneously 
upon patient request.
Primary and secondary outcome measures
The primary outcome parameter was duration of sensory block. Secondary outcome 
parameters included duration of motor block, duration of sensory and motor block of 
individual nerves, block onset time, time to !rst request for additional postoperative pain 
treatment (TTFR) and patient satisfaction (NRS 0-10) with the anesthetic technique. 
After injection of the local anesthetic solution, the onset of sensory and motor block was 
assessed every 5 min, until 30 min after injection. Sensory block of the medial antebrachial 
cutaneous, musculocutaneous, radial, median and ulnar nerves was assessed by pinprick. 
Sensory block was scored on a three-point scale as 0 = absent, 1 = partial and 2 = complete. 
At the same intervals, motor block of the musculocutaneous, radial, median and ulnar nerve 
was assessed (see Table 1) on a similar three-point scale (0 = no, 1 = partial and 2 = complete 
motor block). A complete overall sensory block was de!ned as a total score of 10; complete 
overall motor block was de!ned as a total score of 8.
Conc, dose & vol of LA and duration of ABPBConc, dose & vol of LA and duration of ABPB
Table 1. Baseline Characteristics
Group A (n=15) Group B (n=15) Group C (n=15)
Sex, no. M/ no. F 2/13 6/9 7/8
Age (yr) 59±9 49±13 53±15
Height (cm) 165±7 172±8 171±11
Weight (kg) 71±13 75±7 78±17
ASA classi!cation, no. 1/no. 2/ no. 3 3/10/2 10/5/0 7/8/0
Duration of surgery (min) 24±17 27±25 34±27
Site of surgery, no. left/ no. right 5/10 5/10 5/10
Type of surgery:
- carpal tunnel release, no. 3 2 4
- trapezoidectomy, no. 6 1 2
- removement of osteosynthesis 
material, no.
2 4 1
- arthrodesis of !nger, no. 0 2 1
- release trigger !nger, no. 2 2 3
- arthrodesis of wrist, no. 0 1 2
- other, no. 2 3 2
Group A: 20 mL mepivacaine 1.5%. Group B: 30 mL mepivacaine 1.0%. Group C: 30 mL mepivacaine 1.5%. 
Values are absolute numbers, mean ± SD. 
Upon arrival at the recovery, offset of sensory and motor block was assessed every 15 min in 
the same manner as preoperatively until full recovery. The primary outcome parameter was 
overall duration of sensory block de!ned as the time from t = 0 until the !rst postoperative 
measurement where total sensory score had returned to zero. Overall duration of motor 
block was de!ned as the time from t = 0 until the !rst postoperative measurement where 
total motor score had returned to zero. Block onset time was de!ned as the time from t = 0 
until the time sensory respectively motor score was maximal. TTFR was de!ned as the time 
interval from t = 0 until the time the !rst request for postoperative analgesia was made.
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Sample size, randomization and blinding
The sample size calculation was similar to our previous study7 and based on the overall 
duration of sensory block. In previous research, we7, Bugamelli et al.8, and Robaux et al.9 
found a variation (SD) in duration of sensory peripheral nerve block with mepivacaine of ± 47 
min (47, 45 and 43 min respectively). Based on these data, the sample size required to have 
a 90% probability of detecting a difference of 60 min (approximately 25%) in duration of 
the ABPB between the groups (two sided, level of signi!cance 0.05) is 13 patients per group. 
Compensating for variations in the standard deviation, we chose to include 15 patients 
per group. A computer-generated sequence of random numbers in 3 blocks of 15 and a 
1:1:1 allocation was used for randomization. The allocation sequence was concealed from 
the researcher assessing and enrolling patients in sequentially numbered, sealed, opaque 
envelopes made by an independent researcher, not involved in the study. 
A computerized database automatically assigned a study number to each patient assessed 
for eligibility. Once included in the study, the study number of the patient was written on the 
sealed randomization envelopes by the researcher. On the day of surgery the envelope was 
handed to an anesthetic nurse not involved in the study. The anesthetic nurse prepared the 
study medication according to the allocated group written on the card inside the envelope, 
wrote the study number of the patient on the card and resealed the envelope. 
Patients with speci!c withdrawal criteria, as mentioned earlier in the methods section, 
were excluded and replaced. After 45 patients were included in the study, an independent 
researcher not involved in the study made additional sealed envelopes for the patients 
replacing the excluded patients, randomized and sequentially numbered to conceal 
treatment allocation for the observer. 
At the conclusion of the study, all resealed envelopes were checked by an independent 
researcher not involved in the study, for any violations of the group allocation.  
The anesthetic nurse that prepared the study medication was allowed to disclose allocation 
to the anesthesiologist that performed the block procedure. Both patients and researcher 
were blinded for the volume and concentration of anesthetic solution used.
 
Statistical analysis
Per-protocol analysis was conducted using GraphPad Prism 6 software (GraphPad Software 
Inc, San Diego, CA). 
For statistical comparison between the groups of overall sensory block (primary outcome 
parameter), motor block and the duration of individual nerve blocks one-way ANOVA 
analysis was used and Tukey post-hoc analyses were conducted. Block onset time and 
patient satisfaction (NRS 0-10) with the anesthetic technique was compared between groups 
with Kruskall Wallis test. 
For between group comparison on baseline characteristics Chi square test and Kruskall 
Wallis test were used. All tests were 2-sided, and a p-value ≤ 0.05 was considered statistically 
signi!cant. Frequency distribution was tested using Kolmogorov-Smirnov test for normality. 
Data are presented as mean (95% con!dence interval) or median [range] as appropriate. 
 
Results 
In total, 45 patients were randomized, 15 patients per group. Four patients were excluded 
and replaced. Reasons for withdrawal were block failure (three patients in Group B) and 
patient consent withdrawal (one patient in Group A). All patients received the allocated 
intervention. A CONSORT "owchart is shown in Fig. 1. Baseline characteristics of the three 
groups did not differ signi!cantly and are described in Table 1. 
Thirty minutes after block placement, a complete sensory block was con!rmed in 13 patients 
in Group A, 7 patients in Group B and 13 patients in Group C (p=0.006). Motor block was 
complete in 13 patients in Group A, 10 patients in Group B and 14 patients in Group C. Data on 
sensory and motor block scores of individual nerves after 30 min are shown in Table 2. 
Table 2. Block Scores of Individual Nerves at 30 Minutes
Group A (n = 15) Group B (n = 15) Group C (n = 15)
Nerve Score
2
Score
1
Score
0
Score
2
Score
1
Score
0
Score
2
Score
1
Score 
0
Med. Anteb. Cut. sens 14 1 - 14 1 - 15 - -
Musculocutaneous sens 13 2 - 14 1 - 15 - -
Musculocutaneous mot 13 2 - 12 3 - 14 1 -
Radial sens 14 1 - 10 5 - 14 1 -
Radial mot 14 1 - 12 2 1 13 2 -
Median sens 14 1 - 12 3 - 15 - -
Median mot 13 2 - 14 1 - 15 - -
Ulnar sens 14 1 - 13 1 1 14 1 -
Ulnar mot 14 1 - 14 1 - 15 - -
Group A: 20 mL mepivacaine 1.5%; Group B: 30 mL mepivacaine 1.0%; Group C: 30 mL mepivacaine 1.5%. 
Med. anteb. cut.: medial antebrachial cutaneous nerve; sens: sensory block score, mot: motor block 
score. Block was scored on a three-point scale as 0 = absent, 1 = partial and 2 = complete. 
Conc, dose & vol of LA and duration of ABPBConc, dose & vol of LA and duration of ABPB
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Patients assessed for eligibility
(n = 203)
Excluded (n = 154)
- Not eligible (n = 19)
- No consent (n = 41)
- No time for consent (n = 78)
- Not reached by phone (n = 16)
Randomized
(n = 45)
Allocated to group A (n = 15)
Received allocated intervention (n = 15)
Allocated to group B (n = 15)
Received allocated intervention (n = 15)
Withdrawal (n = 1)
- Withdrawal of consent (n = 1)
Withdrawal (n = 3)
- Block failure (n = 3)
Withdrawal (n = 0)
Allocated to group C (n = 15)
Received allocated intervention (n = 15)
Analyzed (n = 15) Analyzed (n = 15) Analyzed (n = 15)
Replaced (n = 1) Replaced (n = 3) Replaced (n = 0)
Fig. 1. Flowchart of patients enrolled in the study.
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Sensory block, as well as motor block duration, differed signi!cantly between groups:  
p = 0.012 and p = 0.016, respectively (Table 3). Post-hoc-between-group analyses showed 
a statistically shorter sensory and motor block duration of 44 min (20 %) in Group B when 
compared with Group C. Sensory and motor block duration in group A did not differ 
signi!cantly from group B and C. Data on between-group differences of sensory and motor 
block duration are shown in Fig. 2 and Table 4. 
 
Table 3. Duration of Axillary Plexus Nerve Block
Group A: 20 mL mepivacaine 1.5%; Group B: 30 mL mepivacaine 1.0%; Group C: 30 mL 
mepivacaïne 1.5%; 
Group A
(n = 15)
Group B
(n = 15)
Group C
(n = 15)
p-value
Block duration (min)
  Overall sensory 256 ± 46 (186 – 363) 226 ± 31 (168- 274) 270 ± 39 (202 – 333) 0.012
  Overall motor 254 ± 50 (186 – 363) 220 ± 36 (144 – 262) 264 ± 37 (202 – 305) 0.016
Block duration (min)
Med. Anteb. Cut. nerve
  Sensory 222 ± 37 (165 – 292) 197 ± 42 (100 – 262) 247 ± 47 (118 – 303) 0.010
Musculocutaneous 
nerve
  Sensory 213 ± 40 (141 – 271) 196 ± 38 (144 – 262) 215 ± 53 (118 – 333) 0.446
  Motor 224 ± 33 (165 – 277) 188 ± 43 (115 – 243) 216 ± 35 (171 – 296) 0.031
Radial nerve
  Sensory 228 ± 40 (180 – 307) 207 ± 23 (170 – 240) 227 ± 40 (185 – 295) 0.328*
  Motor 229 ± 40 (165 – 307) 209 ± 35 (144 – 262) 258 ± 43 (202 – 305) 0.003
Median nerve
  Sensory 236 ± 44 (156 – 307) 204 ± 35 (145 – 251) 249 ± 43 (162 – 310) 0.015
  Motor 245 ± 48 (156 – 322) 200 ± 42 (144 – 262) 241 ± 30 (195 – 295) 0.015**
Ulnar nerve
  Sensory 238 ± 47 (186 – 363) 211 ± 40 (145 – 274) 249 ± 53 (133 – 310) 0.087
  Motor 243 ± 57 (156 – 363) 209 ± 45 (144 – 262) 257 ± 37 (185 – 303) 0.025
med. anteb. cut. nerve: medial antebrachial cutaneous nerve. ano data because of a postoperative cast 
or bandage in 6 patients in Group A, 5 patients in Group B and 8 patients in Group C. bno data because of 
a postoperative cast or bandage in 3 patients in group A, 2 patients in Group B and 2 patients in Group C. 
Values are mean (95% CI). Bold data represent statistically signi!cant differences 
Conc, dose & vol of LA and duration of ABPBConc, dose & vol of LA and duration of ABPB
Table 4. Groupwise Comparisons of Block Duration
Group A vs Group B Group B vs Group C Group A vs Group C
Difference
(95% CI)
p-value Difference
(95% CI)
p-value Difference
(95% CI)
p-value
Block duration (min)
  Overall sensory 30 (-5 – 65) 0.100 -44 (-79 – -9) 0.010 -14 (-49 – 21) 0.599
  Overall motor 34 (-3 – 70) 0.079 -44 (-80 – -7) 0.017 -10 (-47 – 27) 0.787
Block duration (min)
Med. Anteb. Cut. nerve
  Sensory 24 (-13 – 62) 0.260 -50 (-87 – -12) 0.007 -25 (-63 – 12) 0.244
Musculocutaneous 
nerve
  Sensory 17 (-22 – 56) 0.550 -19 (-58 – 20) 0.482 -2 (-41 – 37) 0.993
  Motor 36 (2 – 69) 0.031 -28 (-61 – 5) 0.110 7 (-26 – 41) 0.848
Radial nerve
  Sensory 22 (-18 – 61) 0.375 -21 (-63 – 22) 0.451 1 (-43 – 44) 0.999
  Motor 20 (-13 – 52) 0.320 -49 (-81 – -16) 0.002 -29 (-62 – 3) 0.086
Median nerve
 Sensory 32 (-4 – 69) 0.091 -44 (-80 – -8) 0.014 -12 (-48 – 24) 0.709
 Motor 45 (5 – 84) 0.024 -41 (-79 – -2) 0.039 4 (-35 – 44) 0.963
Ulnar nerve
 Sensory 27 (-15 – 70) 0.272 -38 (-80 – 4) 0.082 -11 (-53 – 32) 0.818
 Motor 34 (-8 – 76) 0.137 -48 (-91 – -6) 0.023 -15 (-57 – 28) 0.684
Group A: 20 mL mepivacaine 1.5%. Group B: 30 mL mepivacaine 1.0%. Group C: 30 mL mepivacaine 
1.5%; med. anteb. cut. nerve: medial antebrachial cutaneous nerve; CI: con!dence interval. Values are 
calculated differences (95% con!dence interval of the difference). Multiplicity adjusted p-values are 
given. Bold data represent statistically signi!cant differenes
Because of the presence of a postoperative cast, offset of sensory block of the radial nerve 
could not be evaluated in 19 patients (6, 5 and 8 patients in Group A, B and C respectively).  
In these patients maximum postoperative sensory block score was 8 and overall sensory 
block duration was de!ned as the time until the total sensory score had returned to zero.  
The offset of motor block of the median nerve could not be tested in 7 patients (3, 2 and 2 
patients in Group A, B and C respectively). In these patients maximum postoperative motor 
block score was 6 and overall motor block duration was de!ned as the time until the total 
motor score was returned to zero. 
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Only seven patients requested additional postoperative pain medication (four in Group 
A, one in Group B and two in Group C). Because of the limited number of data on TTFR, no 
average TTFR was calculated. Patient satisfaction with the anesthetic technique (NRS, on a 
scale 0 – 10) was comparable between Groups; 8.8±0.8 in Group A, 8.7 ± 1.7 in Group B and 8.9 
± 1.1 in Group C (p=0.76). 
Twenty-eight patients received sedation upon request during surgery. In all included 
patients sensory block was adequate, none of the patients requiring conversion to 
general anesthesia. None of the patients showed signs or symptoms of local anesthetic 
systemic toxicity during the study procedure. In our hospital all patients are screened for 
postoperative nerve damage three weeks after surgery. None of the patients enrolled in the 
study expressed any sign of nerve damage at the postoperative screening.
Discussion
Because of the inseparable relation between dose, volume and concentration, the issue 
which of these three entities is the major determinant of duration of nervous blockade 
is complex. In this study we compared the effects of equal doses in different volume/
concentration, as well as different dose/concentration in equal volumes, and different 
volume/dose in equal concentrations of mepivacaine for ABPB in order to determine whether 
duration of sensory and motor blockade in is mainly affected by volume, concentration or 
dose. 
Our results show that a higher dose and concentration administered results in a longer 
duration of sensory and motor block. When comparing the groups with equal concentrations 
in our study, no difference was found in block duration, despite the difference in dose and 
volume, suggesting a role for concentration and not for dose in determining block duration. 
When comparing the groups with equal dose, there is a tendency for a longer duration for 
sensory and motor block in the group with higher concentration and smaller volume. As it 
is unlikely that a smaller volume would explain this non-signi!cant trend, this may indicate 
that concentration is proportional to the duration of nerve blockade when using equal doses. 
Serradell et al.10 found no differences in the duration of analgesia when using 36 mL, 28 mL 
or 20 mL of mepivacaine 1% for ABPB, suggesting no relation between volume or dose and 
duration of analgesia. On the other hand, several others reported a direct relation between 
dose and duration,7,11,12 although in these studies the higher doses were associated with 
higher volumes as well. Therefore it is unclear whether the effect is to be attributed to dose, 
volume or a combination of both. In a study using multivariate Cox regression to assess the 
effect of different volumes and concentrations of ropivacaine on the duration of analgesia 
following interscalene block for shoulder surgery, Fredrickson et al.13 concluded that both 
volume and concentration affect duration independently.
In a previous study7 comparing 40 mL and 15 mL mepivacaine 1.5% for ABPB, we reported 
that the volume/dose reduction of 62.5% resulted in a shorter overall duration of sensory and 
motor block of respectively 17% and 19%. In the present study we found that a dose reduction 
of 33% did not result in a reduction of block duration (Group A versus Group C). Although 
comparing results from different studies should be done with caution, the methodology of 
our present and previous study7 is identical. Combining the observations from both studies, 
it seems that the relation between volume/dose and the duration of nervous blockade is not 
linear. Reducing the volume/dose of mepivacaine 1.5% from 600 mg (40 mL) to 300 mg (20 
mL) results in a modest change in the median duration of nervous blockade of approximately 
5%; a further decrease to 225 mg (15 mL) results in a decrease in duration of approximately 
18% (Fig. 3). It seems therefore that in ABPB with mepivacaine 1.5%, the optimal balance 
between volume/dose reduction without signi!cantly affecting duration of nervous blockade 
is 20 mL. 
Three patients were excluded from the study because of block failure, all in Group B. While 
this may be due to the lower concentration of mepivacaine, our study was not set up nor 
powered to assess success rate of the different concentrations. In addition, from a clinical 
perspective, 1% mepivacaine may not be a suitable choice for ABPB, given the observed 
failure rate, the inferior onset characteristics, and the shortened duration.
In the patients randomized to group C we exceeded the maximum recommended dose of 4.5 
mg/kg mepivacaine. Maximum recommended doses of local anesthetics are usually provided 
by the manufacturer with the obvious purpose of minimizing the incidence of systemic 
toxicity, but that does not mean that these recommendations are tantamount to safety.  
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Fig. 2. Duration of overall sensory block (a) and overall motor block (b) per Group. Group A: 20 mL 
mepivacaine 1.5%. Group B: 30 mL mepivacaine 1.0%. Group C: 30 mL mepivacaine 1.5%.
Dots represent individual patients, the horizontal lines with error bars represent mean with SD. *p<0.05
Fig. 3. Combined data on sensory block duration (a) and motor block duration (b) of the present study 
and 13 patients receiving 15 mL and 15 patients receiving 40 mL mepivacaine 1.5% from previously 
published work.7
Data are presented as mean with SD. *p<0.005
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On the contrary, maximum recommended doses are controversial because they are neither 
evidence based nor speci!c for site of injection or type of block.14,15 In clinical practice larger 
doses are frequently used and it is our experience that 450 mg mepivacaine for axillary block 
in adult patients is well within the margin of safety.
A limitation of our study is that we were not able to collect postoperative data of all nerves 
in all patients because of the presence of a cast or a compression bandage. However, there 
were no signi!cant differences in the duration of sensory and motor block between the 
different nerves within each group, with the exception of motor block duration of the 
musculocutaneous nerve in Group C, and we therefore think that the effect of the missing 
data on the conclusion of our paper is limited. 
A second limitation is that our power analysis was based on a clinically relevant difference 
of 60 min, whereas in retrospect and from a scienti!c perspective smaller differences may 
also be interesting. The difference in duration between groups A and B is not statistically 
signi!cant, but intriguing nevertheless and possibly a larger sample size would have 
unveiled a signi!cant difference. Future research will focus on further investigating the 
effect of local anesthetic concentration on duration of sensory and motor block. 
In conclusion, a decrease in volume from 30 to 20 mL mepivacaine does not in"uence block 
duration, but a higher dose and concentration in equal volumes of 30 mL results in a longer 
duration of sensory and motor block in ABPB. 
Acknowledgements
Assistance with the article: None declared
Financial support and sponsorship: This study was supported entirely by internal funds of the 
department of Anaesthesiology, Sint Maartenskliniek, Nijmegen, The Netherlands.
References
1. Marhofer P, Greher M, Kapral S. Ultrasound guidance in regional anaesthesia. British Journal of Anaesthesia 
2005; 94:7-17.
2. Casati A, Baciarello M, Cianni S,, et al. Effects of ultrasound guidance on the minimum effective anaesthetic 
volume required to block the femoral nerve. British Journal of Anaesthesia 2007; 98:823-827.
3. Eichenberger U, Stöckli S, Marhofer P,, et al. Minimal Local Anesthetic Volume for Peripheral Nerve Block. 
Regional Anesthesia & Pain Medicine 2009; 34:242-246.
4. Marhofer P, Eichenberger U, Stöckli S, et al. Ultrasonographic guided axillary plexus blocks with low 
volumes of local anaesthetics: a crossover volunteer study. Anaesthesia 2010; 65:266-271.
5. O’Donnell BD, Iohom G. An estimation of the minimum effective anesthetic volume of 2% lidocaine in 
ultrasound-guided axillary brachial plexus block. Anesthesiology 2009; 111:25-29.
6. Eng H, Ghosh S, Chin K. Practical use of local anesthetics in regional anesthesia. Current Opinion in 
Anaesthesiology 2014; 27:382-387.
7. Schoenmakers KPW, Wegener J, Stienstra R. Effect of local anesthetic volume (15 vs 40 mL) on the duration 
of ultrasound-guided single shot axillary brachial plexus block: a prospective randomized, observer-
blinded trial. Regional Anesthesia & Pain Medicine 2012; 37:242-247.
8. Bugamelli S, Zangheri E, Montebugnoli M, et al. One-day surgery for acquired forefoot deformity: sciatic 
nerve blockade with mepivacaine vs mepivacaine+ropivacaine: a prospective, randomized study.  
Minerva Anestesiologica 2007; 73:57-64.
9. Robaux S, Blunt C, Viel E, et al. Tramadol Added to 1.5% Mepivacaine for Axillary Brachial Plexus Block 
Improves Postoperative Analgesia Dose-Dependently. Anesthesia & Analgesia 2004; 98:1172-1177.
10. Serradell A. Comparison of three different volumes of mepivacaine in axillary plexus block using multiple 
nerve stimulation. British Journal of Anaesthesia 2003; 91:519-524.
11. Latzke D, Marhofer P, Zeitlinger M, et al. Minimal local anaesthetic volumes for sciatic nerve block: 
evaluation of ED99 in volunteers. British Journal of Anaesthesia 2010; 104:239-244.
12. Ponrouch M, Bouic N, Bringuier S, et al. Estimation and pharmacodynamic consequences of the minimum 
effective anesthetic volumes for median and ulnar nerve blocks: a randomized, double-blind, controlled 
comparison between ultrasound and nerve stimulation guidance. Anesthesia & Analgesia 2010; 111:1059-
1064.
13. Fredrickson MJ, Abeysekera A, White R. Randomized study of the effect of local anesthetic volume and 
concentration on the duration of peripheral nerve blockade. Regional Anesthesia & Pain Medicine 2012; 
37:495-501.
14. Heavner JE. Let’s abandon blanket maximum recommended doses of local anesthetics. Regional Anesthesia 
& Pain Medicine 2004; 29:524.
15. Rosenberg PH, Veering BT, Urmey WF. Maximum recommended doses of local anesthetics: a multifactorial 
concept. Regional Anesthesia & Pain Medicine 2004; 29:564-75.
 
0303
4948
Chapter 04
Pharmacokinetics of 450 mg 
ropivacaine with and without 
epinephrine for combined 
femoral and sciatic nerve block 
in lower extremity surgery.
A pilot study
Schoenmakers K.P.W., Vree T.B., Jack N.T.M., Van den Bemt B., Van Limbeek J., Stienstra R.
British Journal of Clinical Pharmacology 2013 May; 75(5):1321-1327
 
03
5150
Abstract
Background: No pharmacokinetic data exist on doses of ropivacaine larger than 300 mg for 
peripheral nerve block in man, although in clinical practice higher doses are frequently used. 
The purpose of the present study was to describe the pharmacokinetic pro!le in serum of 
450 mg ropivacaine with and without epinephrine in patients undergoing anterior cruciate 
ligament reconstruction. 
Methods: Twelve patients were randomly allocated to receive a single-shot combined 
sciatic/femoral nerve block with 60 mL of either ropivacaine 0.75% alone (group R, n = 6) or 
ropivacaine 0.75% plus epinephrine 5 μg mL-1 (group RE, n = 6). Venous blood samples for 
total and free ropivacaine serum concentrations were obtained during 48 hours following 
block placement. Pharmacokinetic parameters were calculated using a non-compartmental 
approach.
Results: Results are given as mean (SD) for group R vs. group RE. Total Cmax was 2.81 (0.94) μg 
mL-1 versus 2.16 (0.21) μg mL-1 with a difference of 0.65 (95%CI -0.23–1.53). Tmax was 1.17 (0.30) h 
vs. 1.67 (0.94) h with a difference of -0.50 (95%CI -1.40–0.40). AUC was 28.35 (5.92) µg h mL-1 vs. 
29.12 (7.34) µg h mL-1 with a difference of -0.77 (95%CI -9.35–7.81). The highest free ropivacaine 
concentration per patient was 0.16 (0.08) μg mL-1 vs. 0.12 (0.04) μg mL-1. T1/2 was 6.82 (2.26) h vs. 
5.48 (1.69) h.
Conclusions: Free serum concentrations of ropivacaine with and without epinephrine 
remained well below the assumed threshold of 0.56 µg mL-1 for systemic toxicity. With 
epinephrine coadministration, the peak concentrations tend to be lower and occur later.  
The AUC is equal in both groups.
Pharmacokinetics of high dose ropivacaine
Introduction
In recent years, peripheral nerve block (PNB) has rapidly gained popularity as an anesthetic 
technique for upper and lower extremity surgery. Compared to general anesthesia or central 
neuraxis blockade, interference of PNB with vital functions is minimal and postoperative 
analgesia is excellent. 
For lower extremity surgery, a combination of two or three PNB’s is usually necessary, 
especially when surgery is performed under exsanguination and the use of a tourniquet. 
With the combination of several PNB’s, larger doses then recommended1 are frequently used. 
Despite a plea for abandoning the practice of stating blanket maximum recommended doses 
for local anesthetics2 and a widespread consensus that maximum recommended doses are 
not evidence-based, they continue to be mentioned in textbooks and by manufacturers. In 
the absence of pharmacokinetic data, using higher than recommended doses may pose a 
medico-legal problem in case of local anesthetic systemic toxicity.
Ropivacaine is a long-acting amide local aesthetic. It is structurally closely related to 
bupivacaine, but has a better safety pro!le with regard to central nervous system- and 
cardiotoxicity.3 Unlike bupivacaine, which is a racemate, ropivacaine is a single S(-)-
enantiomer.4
Several authors advocate the addition of epinephrine to large doses of local anesthetics 
in order to reduce the maximum concentration1 or to act as a marker for intravascular 
injection.5 However, the literature is inconclusive whether the addition of epinephrine 5 µg 
mL-1 (1:200,000) offers pharmacokinetic advantages over ropivacaine alone. Some studies did 
!nd an advantage,3,6-8 whereas others did not.9,10
The purpose of the present study is to describe the pharmacokinetic pro!le in serum of 450 
mg ropivacaine with and without epinephrine, in patients undergoing anterior cruciate 
ligament reconstruction under single-shot combined sciatic/femoral nerve block. 
Materials and Methods
Patients
This study was approved by the Independent Review Board Nijmegen and was registered 
at http://www.trialregister.nl (NTR1973) before onset of participant enrolment. Patients 
scheduled for anterior cruciate ligament repair were assessed for eligibility during the 
preoperative screening visit. Patients were informed about the study verbally and in writing 
and written informed consent was obtained from all patients. The study was conducted at 
the Sint Maartenskliniek Nijmegen, The Netherlands according to the Declaration of Helsinki 
and later revisions thereof and in accordance with the ICH guidelines for Good Clinical 
Practice.
Twelve patients (age 18 to 60 years, body weight >70 kg and ASA physical health classi!cation 
I – III) were included. Exclusion criteria included contra-indications for regional anesthesia 
(infection at the injection site, coagulopathy), known hypersensitivity to amide-type 
local anesthetics, known history of peripheral neuropathy, known history of hepatic or 
renal insuf!ciency or use of "uvoxamine, cipro"oxacin, ketoconazole, erythromycin, 
clarithromycin, itraconazole, or rifampicin because of their effect on ropivacaine clearance.1 
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Anesthetic procedure
Using a computer-generated sequence of random numbers and a sealed envelope technique, 
patients were randomly allocated to receive a combined sciatic/femoral nerve block with 
60 mL of either ropivacaine 0.75% (Naropin® AstraZeneca Sweden) alone (group R, n = 6) or 
ropivacaine 0.75% plus 5 μg mL-1 (1:200,000) epinephrine (group RE, n = 6). Blinded syringes 
containing the appropriate study solution were prepared by an anesthesia nurse not 
involved in the block procedure or the subsequent care of the patient. After establishing 
intravenous access and routine monitoring (ECG, non-invasive blood pressure and peripheral 
oxygen saturation), an indwelling venous catheter was placed in the contra lateral fossa 
cubiti for venous blood sampling. 
The sciatic nerve block was carried out with the patient in the lateral decubitus position 
using the parasacral approach,11 a 10 cm stimulating needle and a nerve stimulator. Upon 
request, the patients received mild sedation during the block procedure with 20 mg propofol 
i.v. and 0.5 mg alfentanil i.v. With the nerve stimulator set to deliver 100 nC (1 mA, 0.1 ms) at 2 
Hz, the sciatic nerve was located by either plantar- or dorsi"exion of the foot. Needle position 
was optimized by reducing the current while maintaining the appropriate motor response, 
until the threshold was between 20 and 40 nC. After negative aspiration, 20 mL of local 
anesthetic was injected in the course of one minute in fractionated doses with intermittent 
aspiration after each 5 mL. Upon completion of the injection, time was designated as t = 0.
Immediately following the sciatic nerve block the patient was turned supine and the femoral 
nerve block was performed with a 10 cm stimulating needle under ultrasound guidance 
using a short-axis view and an in-plane technique. As an additional aid to identify the 
femoral nerve, the needle was connected to a nerve stimulator set to deliver 100 nC (1 mA, 
0.1 ms) at 2 Hz. Upon correct needle position as con!rmed by ultrasound visualization and 
a motor response of the quadriceps muscle and after negative aspiration, 40 mL of local 
anesthetic was injected in the course of one minute in fractionated doses with intermittent 
aspiration after each 5 mL. A dose of 40 mL was chosen because it is our experience that this 
higher dose is associated with a higher incidence of complete 3-in-1 block. The total dose of 
both injections adds up to 450 mg ropivacaine with or without 300 μg epinephrine.
Surgery was performed under regional anesthesia. In case of patient discomfort or upon 
patient request, sedation was provided with propofol and remifentanil. There are no known 
interactions of the comedications used (propofol, alfentanil, remifentanil) with ropivacaine 
pharmacokinetics.4
Clinical assessments
During the !rst 120 min, patients were monitored and observed continuously for signs of 
systemic local anesthetic toxicity. 
Sensory block was assessed 15 and 30 minutes after block placement in femoral and sciatic 
nerve supply areas. In case of inadequate anesthesia, intravenous sedation with propofol 
(25 – 60 µg kg-1 min-1) and remifentanil (0.01 – 0.05 µg kg-1 min-1) was initiated before surgical 
incision. 
Blood sampling and assays
Venous blood samples of 5 mL were taken by the investigator (KS) before the !rst injection 
of local anesthetic (-0.25h), and at times 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 6, 12, 18, 24, 36 
and 48 hours. 
Samples were centrifuged within three hours of collection. Serum samples were stored at 
-40°C until assay. After determining total ropivacaine levels in serum, unbound ropivacaine 
levels were determined in ultra !ltrate in 3 samples per patient: the sample with the highest 
total concentration as well as the samples taken immediately before and after. The highest 
concentration of these three measurements was taken as Cumax for each individual patient.
Analysis of ropivacaine in serum and in ultra !ltrate (free concentration) was performed by 
the Laboratory for Toxicology, Therapeutic Drug Monitoring and Pharmaceutical analysis 
of the Department of Hospital Pharmacy at the University Medical Center Groningen, 
Groningen, The Netherlands. A triple quadrupole Quantum LC/MS/MS system with a Surveyor 
MS pump and a Surveyor Plus autosampler (Thermo Scienti!c, Breda, the Netherlands) was 
used. 
To obtain protein-free ultra !ltrate, 300 µL serum was added to a Centrifree Ultra !ltration 
device (Millipore, Amsterdam, the Netherlands) and centrifuged at 1000 g in a 33˚ !xed angle 
centrifuge for 10 minutes.
A 10 μL aliquot of serum or ultra!ltrate was transferred into an autosampler vial and 750 
μL precipitation reagent (methanol 160 ml L-1, ACN 840 ml L-1, and cyanoimipramine 0.04 
mg L-1) with internal standard was added. The vials were then vortexed for 1 minute and 
stored at -20°C for 30 minutes to promote protein precipitation. The vials were centrifuged 
at 11,000 g for 5 minutes and 5 μL of the clear upper layer was injected onto a 50 x 2.1 mm 
HyPURITY Aquastar C18 analytical column (Interscience, Breda, The Netherlands). The mobile 
phase consisted of a gradient mixture of an acid buffer pH = 3.5 (containing ammonium 
acetate 5 g L-1, acetic acid 35 mg L-1 and tri"uoroacetic anhydride 2 mL L-1 of water), water 
and acetonitrile. Acetonitrile for LC-MS, tri"uoroacetic anhydride for LC-MS, and water for 
LC-MS were purchased by BioSolve (Valkenswaard, The Netherlands). Methanol Lichrosolv 
and formic acid were from Merck KGaA (Darmstadt, Germany). Acetic acid 100%, ammonium 
acetate, ammonium formate (98-100%) were from Acros Organics (Geel, Belgium). All 
reagents were of suitable analytical grade. Ultra pure water was obtained from a Milli-Q 
water purifying system (Millipore Corporation, Billerica, MA, USA). The "ow rate was 300 μL 
min-1.
The mass selective detector was operated in electrospray-positive ionization mode and 
performed selected reaction monitoring. High purity nitrogen was used as the sheath gas 
and auxiliary gas, and argon was used as collision gas. Sample analysis was performed 
using the following transitions: ropivacaine m/z 275.0 > 126.2 (collision energy 22 eV) and the 
internal standard (cyanoimipramine) m/z 306.2 > 218.0 (collision energy 39 eV). 
The LLOQ (Lower Limit of Quanti!cation) of ropivacaine was set at 50 µg L-1 of serum (CV = 
7.1%; n = 15) and 5 µg L-1 of ultra !ltrate (CV = 6.8%; n = 15).
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Pharmacokinetic analysis
Because of extravascular administration of ropivacaine at two different injection sites, a non-
compartmental approach was used for the description of the ropivacaine pharmacokinetic 
parameters using MWPharm® (Medi-Ware BV, Zuidhorn, The Netherlands)12. Peak serum 
concentrations (Cmax) and time to reach peak serum concentrations (tmax) were obtained 
directly from the measured serum concentration-time curves. The slope of the terminal 
log-linear portion of the serum concentration-time curve was determined by least-square 
regression to !nd the terminal elimination rate constant (λz). The terminal elimination 
half-life (t1/2) was calculated as 0.693/λz. The area under the serum concentration-time curve 
from time zero to the time of the last quanti!able concentration (AUC(0,tlast)) was calculated 
using the linear trapezoidal rule. The area under the serum concentration-time curve from 
time zero to in!nity (AUC(0-∞)) was calculated as AUC0-∞ = (AUC(0,tlast)) + Clast/λz. The Cumax is 
the highest of three measured free ropivacaine concentrations per patient. The percent free 
concentration of ropivacaine was calculated as (Cu / total ropivacaine concentration in the 
corresponding sample) × 100%.
Sample size and statistics
The aim of this study was to describe the pharmacokinetic pro!le of 450 mg ropivacaine with 
and without epinephrine including the highest free ropivacaine concentrations. We decided 
to study two groups of six patients each. Randomization and blinding was performed to 
eliminate potential preference of anesthesiologists for the addition of epinephrine. The 
GraphPad InStat v.3.10 package (GraphPad Software Inc, San Diego, California) was used 
to perform descriptive statistics and to compare pharmacokinetic parameters using point 
estimates and 95% con!dence intervals of the differences.
All data are presented as mean (SD) [range] or proportions. 
Results
Twelve patients completed the study protocol, six in each group (Table 1).
Table 1. Patient Characteristics
Group R Group RE
Sex (M/F) 5/1 4/2
Age (yr) 27 (8) 31 (13)
Weight (kg) 90 (21) 81 (12)
Height (m) 1.82 (0.10) 1.77 (0.06)
BMI (kg m-2) 27 (3) 26 (3)
Group R: Ropivacaine 450 mg without epinephrine. Group RE: Ropivacaine 450 mg  
with epinephrine 5 µg mL-1. Values are proportions or mean (SD).
Clinical outcome measures
Signs for systemic toxicity of local anesthetics were not observed. 
The time to complete the femoral nerve block after completion of the sciatic nerve block was 
6.2 (1.6) [3-8] minutes. Nine patients underwent surgery without need for additional sedation 
(!ve (R) and four (RE) patients), whereas three patients received sedation at any time during 
surgery due to patient discomfort (one (R) and two (RE) patients). Sedation was provided with 
a short acting sedative (propofol) and a short acting opioid drug (remifentanil) and was mild, 
patients maintaining spontaneous respiration at all times. None of the patients required 
conversion to general anesthesia.
Pharmacokinetics
Figures 1a and 1b show the individual and average concentration-time curves. Figure 2 shows 
these curves in detail during the !rst six hours. Total ropivacaine concentrations became < 
LLOQ (0.050 µg mL-1) in all patients 35 – 50 hr after administration. 
Fig. 2.
Mean (SD) serum concentration-time curves during the !rst 6 hours of ropivacaine without 
(solid dots) and with epinephrine coadministration (open dots). LLOQ = 0.050 μg mL-1.
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Fig. 1 a + b.
Individual (dotted lines) and mean with SD (solid lines) serum concentration-time curves of 
ropivacaine 450 mg without (!g.1a) and with epinephrine 5 μg mL-1 coadministration (!g.1b). 
Mean (SD), free concentration added. LLOQ = 0.050 μg mL-1.
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Table 2 shows data on Cmax, tmax and other pharmacokinetic parameters, as well as the 95% 
con!dence intervals for their differences. The measured maximum total concentration 
(Cmax) in group R was 2.81 (0.94) μg mL-1 and 2.16 (0.21) μg mL-1 in group RE. The 95% CI for the 
difference was from -0.23 to 1.52 µg mL-1 (p=0.13). The measured time to reach the maximum 
concentration (tmax) was 1.17 (0.3) h in group R versus 1.67 (0.94) h in group RE. The 95% CI for 
the difference was from -1.40 to 0.40 h (p=0.25). Elimination half-life (t1/2) was 6.82 (2.26) h in 
group R and 5.48 (1.69) h in group RE.
Table 2. Pharmacokinetic Parameters.
Group R Group RE Difference group R 
versus RE, (95% CI)
Cmax (μg mL-1) 2.81 (0.94) [1.94 – 3.82] 2.16 (0.21) [1.68 – 2.29] 0.65 (-0.23 – 1.53)
Tmax (h) 1.17 (0.30) [0.43 – 1.26] 1.67 (0.94) [1.25 – 3.35] -0.50 (-1.40 – 0.40)
Cumax (μg mL-1) 0.16 (0.08) [0.07 – 0.30] 0.12 (0.04) [0.05 – 0.17] 0.04 (-0.04 – 0.12)
AUC (μg h mL-1) 28.35 (5.92) [22.49 – 39.23] 29.12 (7.34) [19.83 – 41.08] -0.77 (-9.35 – 7.81)
T ½ (h) 6.82 (2.26) [4.71 – 9.73] 5.48 (1.69) [3.02 – 8.07] 1.34 (-1.23 – 3.91)
Groups as de!ned in Table 1. Values are mean (SD) [range]. Cmax = maximum total ropivacaine 
concentration; Tmax = time to Cmax; Cumax = maximum free ropivacaine concentration; AUC = area under 
the serum concentration-time curve from time zero to in!nity; T½ = elimination half-life.
Table 3 presents raw data on the highest free concentration per patient. The measured 
highest free ropivacaine concentration (Cumax) was 0.16 (0.08) μg mL
-1 in group R and 0.12 
(0.04) μg mL-1 in group RE. The 95% CI for the difference was from -0.12 to 0.04 µg mL-1 
(p=0.31). The percentage of free ropivacaine calculated from all samples was 5.1% (1.6) [2.2% 
to 8.0%] in group R and 5.2% (1.7) [2.4% to 8.5%] in group RE. Free ropivacaine concentrations 
are also shown in Figures 1a and 1b. 
Table 3. Highest Measured Free Ropivacaine Serum Concentration per Patient and Corresponding 
Total Ropivacaine Serum Concentration.
Group R Group RE
Patient Time 
(h)
Total conc. 
(μg mL-1 )
Free conc. 
(μg mL-1 )
Patient Time 
(h)
Total conc. 
(μg mL-1 )
Free conc. 
(μg mL-1 )
2 1.5 4.09 0.21 1 1.5 1.99 0.17
3 1.25 1.75 0.14 4 0.75 2.33 0.15
5 0.75 2.25 0.13 6 1.5 1.79 0.09
8 1.0 2.10 0.07 7 1.25 2.12 0.05
9 1.25 2.40 0.13 10 3.0 2.10 0.14
11 1.5 3.89 0.30 12 1.25 2.37 0.14
Groups as de!ned in Table 1. Time points are at Cumax.
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Discussion
This is the !rst study describing the pharmacokinetic pro!le in serum of 450 mg ropivacaine 
with and without epinephrine for combined sciatic/femoral nerve block. 
In the current literature, several studies report pharmacokinetic data on ropivacaine doses of 
300 mg. Cuvillon and colleagues13 and Vanterpool and colleagues14 used 300 mg ropivacaine 
with epinephrine (1:200,000 and 1:400,000 respectively) in combined lumbar plexus/sciatic 
nerve block and found a Cmax for total ropivacaine of 1.84 (0.59) µg mL
-1 and 1.56 (0.35) µg mL-1 
respectively and a tmax less than 1 hour. In these studies, samples were only taken until 90 
min13 and 4 h14 after injection and therefore they do not provide data on elimination half-
lives. Wank and colleagues15 and Pere and colleagues16 studied the pharmacokinetic pro!le of 
300 mg ropivacaine without epinephrine in axillary brachial plexus block and found a Cmax of 
2.3 (0.8) µg mL-1 and 1.8 (0.5) µg mL-1 respectively. In both studies, tmax was less than 1 hour and 
elimination half-lives were 6.1 (1.8) h15 and 8.4 (10.5) h16. Although these studies differ from 
ours with respect to dose and site of injection, the tmax and t1/2 are comparable to the data 
obtained in our group R (tmax = 1.17 (0.3) h; t1/2 = 6.82 (2.26) h).
The major concern when using high doses of local anesthetic is systemic toxicity. If and when 
systemic toxicity occurs, depends on the free ropivacaine serum concentration exceeding 
the toxic threshold. Ropivacaine in serum is mainly bound to α1-acid glycoprotein (AAG) 
and the percent free concentration is approximately 6%.17 In a study in healthy volunteers 
receiving iv. ropivacaine, Knudsen and colleagues18 de!ned the toxic threshold for free 
ropivacaine in arterial samples as 0.56 [range: 0.34 – 0.85] μg mL-1. In our study we took 
venous samples; however, when absorption into the central compartment is slow (as is the 
case with perineural injection), arterial and venous concentrations will be comparable. The 
highest free ropivacaine serum concentration we found in our study remains well below the 
threshold of 0.56 μg mL-1. Systemic toxicity may occur directly in relation with the injection 
of local anesthetic, or after a delay. Direct systemic toxicity occurs in case of accidental 
intravenous injection; serum concentration rises rapidly and the interval between injection 
and the onset of symptoms is characteristically short (1-2 min). Excluding accidental 
intravenous injection, the free ropivacaine serum concentration may still rise above the 
toxic threshold and result in systemic toxicity. In the latter case, the concentration-time 
pro!le is determined by total dose and absorption from the site of injection into the central 
compartment, as well as by distribution and elimination. In this case, the delay between the 
injection and the onset of symptoms is much longer (>15 min). 
A limitation of the present study is the small numbers in each group. Our study groups 
contained six patients each and authorative statements about safety obviously require 
larger numbers. However, in the past 10 years, more than 5,000 patients at our institution 
have received a combined sciatic/femoral nerve block with 450 mg of ropivacaine. During 
this period, we have observed only one patient with mild signs of delayed systemic toxicity 
(anxiety and restlessness, 45 min after injection) that resolved within minutes without 
treatment. 
A second limitation of this study is the relatively high total dose of ropivacaine. With 
the introduction of ultrasound, there has been a rapid re!nement in block placement 
techniques. The use of ultrasound allows a reduction in local anesthetic volume and dose 
without compromising block ef!cacy, reducing the need for large doses as described in this 
study. However, doses exceeding the maximum recommended dose of 300 mg ropivacaine 
still occur regularly. As such there remains a need for pharmacokinetic data on doses of 
ropivacaine for peripheral nerve block that are higher than the maximum recommended 
dose.
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The rationale for adding epinephrine to reduce the maximum plasma concentration is local 
vasoconstriction at the site of injection19 thereby slowing absorption. Several studies found 
a decrease in Cmax and an increase in tmax as a result of adding epinephrine to ropivacaine for 
epidural,7,8 caudal20 or regional6 (thoracic paravertebral block) anesthesia. On the other hand, 
for perivascular subclavian block, Hickey et al.9 found no effect on pharmacokinetics (Cmax, 
tmax or AUC) after the addition of epinephrine to ropivacaine.
In our study, the peak concentrations tend to be lower and occur later with epinephrine 
coadministration. The AUC is equal in both groups.
To document the pharmacokinetic safety of higher than recommended doses of ropivacaine, 
as well as to study the effect of adding epinephrine, adequately powered studies are 
necessary. The results of this study may serve as a basis for such studies.
In conclusion, this is the !rst study describing the pharmacokinetic pro!le in serum of 450 
mg ropivacaine with and without epinephrine for combined sciatic/femoral nerve block. 
Free serum concentrations of ropivacaine in both groups remained well below the assumed 
threshold of 0.56 µg mL-1 for systemic toxicity. 
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Abstract
Background: Duration of peripheral nerve blocks depends on multiple factors. Both 
technique and type of local anesthetic used, either with or without adjuncts, may result in 
different duration times of the block. The purpose of the present study was to compare the 
duration of postoperative analgesia of 30 mL ropivacaine 0.75% with or without epinephrine 
for popliteal sciatic nerve block.
Methods: Thirty-eight patients were included to receive ultrasound guided continuous 
popliteal nerve block with ropivacaine 0.75% either without (ROPI) or with epinephrine  
5 μg/mL (ROPI-EPI) for ankle fusion, subtalar fusion, or a combination of both. The primary 
outcome parameter was the duration of postoperative analgesia as re"ected by the time 
to !rst request for postoperative analgesia (TTFR) through the popliteal nerve catheter. 
Secondary outcome measures included the onset of sensory and motor block and NRS score 
for pain at rest and during movement.
Results: Thirty patients, 15 in each group, were studied. Eight patients were withdrawn 
because of speci!c withdrawal criteria described in the protocol and replaced according 
to their group allocation. Median [interquartile range] TTFR was 463 [300-1197] min and 
830 [397-1128] min for the ROPI vs ROPI-EPI group respectively. Hodges Lehman median 
difference between groups was 71 min (95% CI: -415 – 473 min). There was no difference in 
any clinical outcome measure between the groups.
Conclusions: The results of this study did not show any signi!cant increase in the duration 
of postoperative analgesia by adding epinephrine to ropivacaine for popliteal nerve block. 
This may be due to the intrinsic vasoconstrictive properties of ropivacaine. The absence of a 
signi!cant difference can also be the result of a type II error caused by a large variation in the 
individual TTFR.
Effect of adding epinephrine to ropivacaine on TTFR
Introduction
Duration of peripheral nerve block depends on several factors such as the choice of local 
anesthetic (LA), the site of injection and the presence of adjuncts such as clonidine or 
epinephrine. Epinephrine may be added to (large) doses of local anesthetics (LA) with 
the objective to reduce the maximum plasma concentration1 or to act as a marker for 
inadvertent intravascular injection.2 The rationale for adding epinephrine to reduce the 
maximum plasma concentration is local vasoconstriction at the site of injection,3 thereby 
slowing absorption. A decrease in absorption increases the duration of analgesia.4 The 
literature however, is inconclusive regarding this effect. Several studies !nd a decrease in 
Cmax and an increase in tmax as result of adding epinephrine to ropivacaine for epidural,
5,6 
caudal7 or regional8 (thoracic paravertebral block) anesthesia con!rming a decrease in 
absorption. However, others fail to con!rm prolonged sensory block duration when adding 
epinephrine to ropivacaine.9,10 In a recent study aimed to describe the pharmacokinetic 
pro!le of high dose ropivacaine with and without epinephrine,11 we found an indication 
of prolonged time to !rst request for postoperative analgesia (TTFR) after the addition of 
epinephrine to ropivacaine for combined sciatic/femoral nerve block for anterior cruciate 
ligament reconstruction. In this study of 12 patients,11 3 did not request postoperative 
analgesia (1 in the ROPI-group and 2 in the ROPI-EPI-group). For the remaining patients 
the median TTFR was 17 [12.5-22] h in the ROPI-EPI-group and 3.5 [3-17] h in the ROPI-group. 
Because of the small number of patients, these data have not been included in the original 
publication. 
The purpose of the present study is to compare the duration of postoperative analgesia of 30 
mL ropivacaine 0.75% with or without epinephrine for popliteal sciatic nerve block. 
Materials and Methods
Patients
This prospective double blinded (for observer and patient) randomized study was 
approved by the Independent Review Board Nijmegen (protocol number NL39628.072.12, 
date of approval 28-02-2012) and was registered at http://www.trialregister.nl (NTR3330, 
keyword TTFR) before onset of participant enrolment. The study was conducted at the Sint 
Maartenskliniek Nijmegen, The Netherlands according to the Declaration of Helsinki and 
later revisions thereof and in accordance with the ICH guidelines for Good Clinical Practice. 
Patients scheduled for continuous popliteal sciatic nerve block for ankle fusion, subtalar 
fusion, or a combination of both were assessed for eligibility during the preoperative 
screening visit. Patients were informed about the study verbally and in writing and written 
informed consent was obtained from all patients. Eligible participants were all adults aged 
18 or over with ASA physical health classi!cation I-III. Exclusion criteria included contra-
indications for regional anesthesia (infection at the injection site, coagulopathy), known 
hypersensitivity to amide-type local anesthetics, known history of peripheral neuropathy, 
inability to understand numerical pain scales, and inability to operate a Patient-Controlled 
Analgesia (PCA) device. Speci!c criteria for withdrawal (and replacement) included: failure 
to perform adequate continuous popliteal sciatic nerve block; pain in the distribution of the 
sciatic nerve upon arrival at the recovery directly postoperatively requiring a therapeutic 
intervention (block failure); and failure to complete the study protocol (e.g. no request for 
postoperative analgesia). 
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Anesthetic procedure
All patients received paracetamol 1000 mg orally three times daily and etoricoxib 90 
mg orally once a day, starting on the morning of surgery for at least 7 days. Intravenous 
access and routine monitoring were established in all patients. According to a computer-
generated sequence of random numbers and a sealed envelope technique, patients received 
continuous popliteal nerve block with ropivacaine 0.75% either without (ROPI, n = 15) or with 
epinephrine 5 μg/mL (ROPI-EPI, n = 15). All popliteal blocks were placed with the patient in 
the lateral decubitus position on the non-dependent side using ultrasound guidance and a 
posterolateral in-plane approach. A nerve stimulator set to deliver 100 nC (1 mA, 0.1 ms) at 2 
Hz was used as an additional aid. The tibial, peroneal and sciatic nerves were identi!ed and 
injection was made at the level of the bifurcation of the sciatic nerve. Thirty mL ropivacaine 
0.75% without or with epinephrine 5 μg/mL was injected in fractionated doses. Time was 
designated t = 0 upon conclusion of the popliteal sciatic nerve block. A perineural catheter 
was inserted through the needle after injection of the loading dose. Upon completion of 
the popliteal nerve block the patient was placed in the supine horizontal position. Because 
surgery was performed under exsanguination and a tourniquet, a single shot ultrasound-
guided femoral or saphenous nerve block with 20 mL mepivacaine was performed to 
facilitate the use of the tourniquet. Surgery was performed under regional anesthesia alone, 
or supplemented with sedation upon patient request. If the planned duration of surgery 
exceeded 120 min, patients received general anesthesia with propofol, remifentanil and a 
laryngeal mask. 
Upon arrival at the recovery room, a PCA-pump (GemStar®, Hospira Inc. Lake Forest, 
Illinois, USA) was connected to the popliteal catheter set up to deliver bolus doses of 10 
mL ropivacaine 0.2%, with a lock-out time of 15 minutes, no background infusion and 
a maximum of 30 mL per 4 hours. The intensity of postoperative pain was evaluated by 
Numeric Rating Scale (NRS, 0-10). Prior to surgery, patients had been instructed to use the 
PCA device to maintain postoperative pain scores at or below NRS 3.
Clinical assessments
Baseline characteristics of participating patients were recorded (i.e. age, length and weight). 
During the !rst 45 minutes after performance of the popliteal nerve block, a blinded observer 
assessed the onset of sensory and motor block every 5 minutes until complete block of the 
tibial and peroneal nerve. Sensory block of the tibial and peroneal nerves was assessed by 
pinprick at the heel of the foot (tibial nerve) and dorsum of the foot between the 1st and 
2nd toe (peroneal nerve). Sensory block was scored on a three-point scale as 0 = absent, 1 
= partial and 2 = complete. Motor function of the tibial (plantar "exion foot) and peroneal 
nerve (dorsal "exion of foot) were also assessed on a three-point scale with 0 = no motor 
block, 1 = partial and 2 = complete motor block. Complete sensory and motor block was 
de!ned as a total score of 8. In those patients that did not have a complete block before the 
beginning of surgery, we assessed block success upon arrival at the recovery room directly 
postoperatively. In these patients, block success was de!ned as absence of pain requiring 
therapy in the distribution of the sciatic nerve distribution area, while patients requiring 
pain relief were deemed failures and were excluded from the study. Type and duration of 
surgery were recorded. At t = 24h the PCA pump was read out and the TTFR was noted. TTFR 
was de!ned as the time from t = 0 until the time that the patient made the !rst request for 
analgesia via the PCA pump. In case no request had been made, sensory and motor block 
were evaluated in the same manner as preoperatively, and ropivacaine consumption was 
checked again at t = 48h. 
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The primary outcome parameter was the duration of postoperative analgesia as re"ected 
by the TTFR. Secondary outcome measures included the onset of sensory and motor block, 
NRS score for pain at rest and during movement directly postoperatively, at t = 24h and if 
necessary at t = 48h and satisfaction score (NRS 0-10) with the anesthetic technique at the 
time of completion of the study.
Sample size and statistical analysis
Taboada et al.12 have reported a duration of 19 ± 3.4 h postoperative analgesia after popliteal 
block with 30 mL ropivacaine 0.75%. Based on these data, the sample size required to have 
an 80% probability of detecting a difference of 20% (two-sided, level of signi!cance 0.05) in 
the duration of postoperative analgesia between the groups was 12 patients per group. We 
chose to include 15 patients per group to compensate for variation in standard deviation. 
Patients with speci!c withdrawal criteria, as mentioned earlier in the methods section, were 
withdrawn and replaced. An independent monitor not involved in further conduction of the 
study made new sealed envelopes according to group allocation of the withdrawn patients.
Data were analyzed using the GraphPad Prism 6 software (GraphPad Software Inc, San Diego, 
CA). Analysis was per protocol. The D’Agostino & Pearson omnibus normality test was used for 
normality testing. Continuous, normally distributed data are presented as mean ± SD [range], 
non-normally distributed data as median [interquartile range]. For statistical comparison 
between the groups, the student-t test for normally distributed data and the Mann Whitney 
U test for nonparametric comparisons was used. In case a parameter is normally distributed 
in one group and non-normally in the other group, the data are presented as median 
[interquartile range] and a nonparametric test used for statistical comparison. The Hodges-
Lehmann estimate was used for calculating the difference between population medians with 
95% CI; the difference between each value in the ROPI group and each value in the ROPI-
EPI group was computed and the Hodges-Lehmann estimate is the median of this set of 
differences. The part of patients without need for postoperative analgesia in group ROPI vs. 
ROPI-EPI were compared using Chi squared test. A p-value < 0.05 was considered statistically 
signi!cant. 
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Results
In order to study 15 patients in each group, 38 patients were included in the study protocol 
between July 2012 and March 2013. A Consort "owchart is shown in Figure 1. Five patients 
in the ROPI group and three in the ROPI-EPI group were withdrawn on account of speci!c 
withdrawal criteria described in the protocol. These included failure to complete the study 
protocol (i.e. no request for postoperative analgesia at t = 48 h; one in each group, and no 
preoperative block assessment; also one in each group) and pain requiring therapy in the 
distribution of the sciatic nerve upon arrival at the recovery directly postoperatively (block 
failure; three in the ROPI group, one in the ROPI-EPI group). There were no signi!cant 
differences in patient characteristics between the two groups (Table 1). 
Table 1. Patient Characteristics
ROPI ROPI-EPI
Sex (M/F) 8/7 9/6
Age (yr) 61 ± 7 56 ±11
Length (cm) 177 ± 12 175 ± 8
BMI (kg/m2) 28 ± 4 30 ± 5
ASA (I/II/III) 4/10/1 5/10/0
Surgery Ankle fusion: 9 (1)
Subtalar fusion: 6
Combination: 0
Ankle fusion: 10 (3)
Subtalar fusion: 4 (1)
Combination: 1
Operation time (min) 87 ± 33 92 ± 33
ROPI: popliteal block with 30 mL ropivacaine 0.75% without epinephrine; ROPI-EPI: popliteal block 
with 30 mL ropivacaine 0.75% with epinephrine 5 µg/mL. Values are proportions, mean ± SD or actual 
numbers. Differences between the groups were not signi!cant. *Patients with medial incision beside 
lateral incision. 
Due to OR logistics, block onset could not be measured at 45 minutes in all patients. In case 
a patient did not have a complete block before the beginning of surgery, block success or 
failure was de!ned as absence or presence of pain requiring therapy in the distribution of 
the sciatic nerve upon arrival at the recovery directly postoperatively. Patients with a failed 
block were excluded and replaced, patients with a successful block remained in study. Table 2 
shows sensory and motor block onset scores for patients with a successful block upon arrival 
at the recovery.
Table 2. Onset Scores of Individual Nerves at Beginning of Surgery
Nerve ROPI ROPI-EPI
Complete Partial Absent Complete Partial Absent
Tibial sensory 4 11 1 9 4 2
Tibial motor 10 3 2 9 5 1
Peroneal sensory 12 3 - 11 4 -
Peroneal motor 11 2 2 10 3 2
Groups as de!ned in Table 1. Values represent numbers of patients. 
Figure 2 shows individual TTFR data points for both groups. Median [IQR] time to !rst request 
for postoperative analgesia was 463 [300-1197] min and 830 [397-1128] min for the ROPI vs. 
ROPI-EPI group respectively. Hodges Lehman median difference between groups was 71 min 
(95% CI: -415 – 473) for the ROPI-EPI vs. ROPI group. There were no differences in any clinical 
outcome measures between the groups (Table 3). 
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Fig. 1. Consort #owchart of patients enrolled in the study
Patients assessed for eligibility
(n = 126)
Excluded (n = 88)
- Not eligible (n = 22)
- No consent (n = 62)
- Logistic reasons (n = 4)
Included
(n = 38)
Allocated to ROPI (n = 20)
Received allocated intervention (n = 20)
Allocated to ROPI-EPI (n = 18)
Received allocated intervention (n = 18)
Wihdrawal (n = 5)
Failure to complete study protocol
- No TTFR (n = 1)
- No preop block assessment (n = 1)
Block failure (n = 3)
Wihdrawal (n = 3)
Failure to complete study protocol
- No TTFR (n = 1)
- No preop block assessment (n = 1)
Block failure (n = 1)
Analyzed (n = 15) Analyzed (n = 15)
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Table 3. Clinical Outcome Measures
ROPI ROPI-EPI p-value
TTFR (min) 463 [300-1197] 830 [397-1128] 0.56
NRS rest at t=24h 1 [0-3] 1 [1-3] 0.70
NRS movement at t=24h 1.5 [0-3] 2 [1-3] 0.47
NRS max during 24 h 4 [2-7] 6 [3-8] 0.17
NRS satisfaction with block 8 [8-9] 9 [8-10] 0.08
Groups as de!ned in Table 1. Values are median [IQR]. TTFR: Time To First Request for postoperative  
analgesia; NRS: Numeric Rating Scores (0-10) 
Fig. 2. Individual data points of time to !rst request for postoperative analgesia
ROPI: popliteal block with 30 mL ropivacaine 0.75% without epinephrine; ROPI-EPI: popliteal 
block with 30 mL ropivacaine 0.75% with epinephrine 5 µg/mL; TTFR: Time To First Request for 
postoperative analgesia. Horizontal lines represent medians ± interquartile range. 
Dotted lines represent t = 24 and 48 hours.
Discussion
The results of this study did not show a signi!cant increase in the duration of postoperative 
analgesia by adding epinephrine to ropivacaine for popliteal nerve block. 
A prolonged duration of postoperative analgesia by adding epinephrine to ropivacaine 
was expected based on our clinical experience. In a previous study, we found an indication 
of prolonged TTFR after the addition of epinephrine 5 μg/mL to 450 mg ropivacaine for 
combined sciatic/femoral nerve block for anterior cruciate ligament reconstruction.11 
However this study was underpowered to make comparisons in TTFR. In the present study 
we were unable to con!rm this expected difference in sensory block duration. Although the 
difference in the median TTFR between the groups is large (367 min), the data show a large 
variation and data in group ROPI are skewed with a long tail and therefore are not normally 
distributed. The Hodges Lehman estimate of the median difference was 71 min (95% CI: -415 – 
473). As a result of the large variation in our data the risk of a type II error is considerable. The 
absence of a statistically signi!cant difference should therefore be interpreted with caution. 
Our results are consistent with previous !ndings by Cederholm9 and Weber10. Cederholm 
found no difference in duration of sensory block during epidural analgesia with 20 mL 
ropivacaine 0.5% or 0.75% either with or without epinephrine 5 μg/mL. Weber did not !nd an 
effect of epinephrine 5 μg/mL added to 20 mL ropivacaine 0.5% and 0.2% on postoperative 
analgesia via a femoral catheter after total knee replacement. 
Epinephrine is thought to prolong block duration based on a decrease in local anesthetic 
absorption due to local vasoconstriction at the site of injection.3 Ropivacaine has intrinsic 
vasoconstrictive properties. Cederholm13 found an inverse dose-response relationship in 
which the weakest solutions of ropivacaine (0.063% and 0.125%) showed the most marked 
reduction in skin blood "ow measured by laser doppler as compared to normal saline. 
Kopacz14 found that subcutaneous injection of ropivacaine 0.25% and 0.75% reduced 
cutaneous blood "ow in pigs to a similar degree at both concentrations also measured 
by laser doppler. The addition of epinephrine to ropivacaine did not alter the maximum 
decrease in blood "ow observed; however epinephrine signi!cantly decreased blood "ow 
when added to saline.
This quality of ropivacaine may also explain the absence of a clinical signi!cant difference in 
block duration of ropivacaine either with or without epinephrine found in our study. 
Our study has several limitations. We did not measure block duration by assessing sensory 
and motor block at regular time intervals, and TTFR is a subjective measure of block duration. 
However, pinprick assessments of sensory block during 24-48h, including night-time, 
is bothersome for patients and, for instance, in the present study impossible due to the 
post-operative cast management. From a clinical perspective duration of analgesia is more 
important than duration of sensory block. We therefore feel that using the TTFR as a tool to 
measure block duration is acceptable.Our decision to replace the two patients (one in each 
group) who made no request for pain relief during 48 h and in whom there were no longer 
signs of sensory sciatic nerve bock is debatable, as it may be argued that both patients had 
a successful sciatic nerve lock. However, since the primary outcome parameter (TTFR) was 
absent in these patients and the sciatic nerve block had worn off, we felt it would have been 
inappropriate to censor these data to 48 h and include them in the analysis.
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Furthermore, anesthesiologists were not blinded for treatment allocation. All block were 
performed by experienced anesthesiologists in a standardized fashion as described in the 
treatment protocol. Since they were not involved in block assessment or in any other way in 
the conduction of the study, we believe that the absence of blinding of the anesthesiologists 
performing the blocks does not affect the results.
Another limitation is that we studied the duration of analgesia of the popliteal nerve block 
for ankle fusion surgery while the cutaneous sensory supply of the medial malleolus is by 
the saphenous nerve. Clendenen and Whalen histologically veri!ed that the saphenous 
nerve innervates not only the skin, but also the periosteum of the medial malleolus and 
joint capsule.15 Because we performed only a single-shot femoral or saphenous nerve block 
with mepivacaine, the TTFR in individual patients may have been triggered by pain in the 
distribution of the saphenous nerve, and thus re"ect the duration of sensory block of the 
femoral or saphenous nerve rather than the sciatic nerve. Standard incision for ankle fusion 
and subtalar fusion is on the lateral side. However, an additional medial incision was made 
in 5/30 patients. In four of these patients the TTFR was > 360 min. Because the duration of 
sensory femoral or saphenous nerve block is shorter, we believe that the effect of pain in the 
distribution of the saphenous nerve on the TTFR is minimal.
In conclusion, we were unable to con!rm an expected difference in the duration of 
postoperative analgesia by adding epinephrine to ropivacaine for popliteal nerve block. This 
may be explained on the basis of the intrinsic vasoconstrictive properties of ropivacaine or 
due to a large variation in the individual TTFR, the absence of a signi!cant difference may 
also be caused by a type II error.
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Abstract
Background: Stimulating catheters offer the possibility of delivering an electrical charge via 
the tip of the catheter. This may be advantageous as it allows verifying if the catheter tip is in 
close proximity to the target nerve, thereby increasing catheter performance.  
This prospective blinded cohort study was designed to investigate whether there is a 
correlation between the minimal electrical charge at the tip of the stimulating catheter, and 
the ef!cacy of the peripheral nerve block (PNB) catheter as determined by 24h postoperative 
morphine consumption.
Methods: Forty adult patients with ASA physical health classi!cation I-III scheduled for upper 
extremity surgery under combined continuous interscalene block and general anesthesia 
were studied. Six patients were excluded from analysis. 
After inserting a stimulating catheter as if it were a non-stimulating catheter for 2-5 cm 
through the needle, the minimal electrical charge necessary to obtain an appropriate motor 
response was determined. A loading dose of 20 mL 0.75% ropivacaine was then administered, 
and postoperative analgesia was provided by a continuous infusion of ropivacaine 0.2%  
8 mL.h-1 via the brachial plexus catheter, and an intravenous morphine patient-controlled 
analgesia (PCA) device. 
Main outcome measures include the minimal electrical charge (MEC) at the tip of the 
stimulating catheter necessary to elicit an appropriate motor response, and the ef!cacy of 
the PNB catheter as determined by 24h postoperative PCA morphine consumption.
Results: Mean (SD) [range] MEC at the tip of the stimulating catheter was 589 (1414)  
[30 – 5000] nC. Mean (SD) [range] 24h morphine consumption was 8.9 (9.9) [0-29] mg.  
The correlation between the MEC and 24h postoperative morphine consumption was 
Spearman’s Rho rs = -0.26, 95% CI -0.56 to 0.09.
Conclusion: We conclude that there is no proportional relation between MEC at the tip of the 
blindly inserted stimulating catheter and 24 h postoperative morphine consumption. 
Stimulating catheter ef!cacy
Introduction
Peripheral nerve block (PNB) is popular among anesthesiologists and patients for peri- and 
postoperative pain relief. PNB can be administered as a single shot or continuously using 
a catheter. For continuous PNB, non-stimulating and stimulating catheters are available. 
Non-stimulating catheters are inserted blindly through the needle after obtaining a 
correct needle position as determined by nerve stimulation (NS) and/or ultrasound. 
Because catheters are usually inserted some distance beyond the needle tip to avoid 
inadvertent dislocation, verifying a correct catheter position is not possible. Therefore, most 
anesthesiologists choose to administer a loading dose through the needle before placing the 
catheter. Whether the catheter tip is correctly placed does not become apparent until after 
the effect of the loading dose has worn off, usually late at night. 
The use of ultrasound has become state of the art for PNB to ensure close proximity of the 
needle tip to the nerve before injecting the local anesthetic. Nevertheless, nerve stimulation 
is still widely used as the sole technique or to double-check needle position. Although 
there is no prede!ned relationship between the minimal electrical charge necessary 
to elicit an appropriate motor response, i.e. a contraction of a muscle innervated by the 
stimulated nerve (MEC), and the actual distance of the needle tip to the target nerve, it is 
generally assumed that the MEC has to be below 50 nanoCoulomb (nC) to ensure proximity 
close enough for effective nerve block1,2 and above 20 nC to avoid inadvertent intraneural 
injection.3 
Stimulating catheters can be inserted while stimulating at the tip of the catheter. The 
expected added value of stimulation during insertion is that by maintaining an appropriate 
motor response, optimal positioning of the tip in close proximity of the nerve can be ensured. 
However, this is based on the assumption that an appropriate motor response with a 
suf!ciently low electrical charge equals adequate positioning of the catheter tip. In other 
words: A low electrical charge necessary to evoke an appropriate motor response signals 
close proximity of the catheter tip to the nerve, whereas an increase in the MEC signals an 
increase in the distance between catheter tip and the nerve. Establishing a correct position 
of the catheter tip not only increases the likelihood of adequate postoperative analgesia, it 
also allows the administration of the loading dose fractionated through the catheter, thus 
reducing the risk of systemic toxicity. An obvious disadvantage is that stimulating catheters 
are more expensive and more needle manipulation may be necessary.
Recent literature has focused on the sensitivity of an appropriate motor response evoked by 
nerve stimulation in determining needle or catheter-nerve contact using ultrasonography 
as a reference.3-7 However, these studies have focused on the false-negative response; i.e. 
no appropriate motor response in case of needle-nerve contact as visualized by ultrasound. 
When an appropriate motor response can be elicited with a low electrical charge, close 
proximity to the nerve is evident. However, when the necessary electrical charge is relatively 
high, or an appropriate motor response is absent, there are three possibilities: the tip of 
the catheter may either still be close enough to the nerve to provide adequate analgesia, or 
it may be at an intermediate distance with partial analgesic effect, or it may be too far off 
and inadequate for postoperative analgesia. One clinical way to evaluate if the tip of the 
catheter is adequately placed, is measuring postoperative morphine consumption: With an 
appropriately placed catheter tip, morphine consumption is expected to be low, whereas 
consumption is expected to increase if the catheter tip is farther off from the nerves. 
One could hypothesize that the relation between MEC and morphine consumption is 
proportional, i.e. there is a linear correlation between the necessary electrical charge at 
the tip of the stimulating catheter and the adequacy of the catheter, justifying the extra 
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manipulation to ensure close proximity to the nerve. The purpose of the present study is to 
investigate whether there is a correlation between the MEC at the tip of the blindly inserted 
stimulating catheter necessary to elicit an appropriate motor response, and the ef!cacy of 
the PNB catheter as determined by postoperative PCA morphine consumption. To investigate 
this hypothesis, we inserted a stimulating catheter as if it were a non-stimulating catheter 
and used the stimulation after placement as a measurement tool. 
Materials and Methods
Ethics
Ethical approval for this study (Ethical Committee N° IRBN2009004) was provided by the 
Independent Review Board Nijmegen (Chairperson Dr. P. Koopmans) on 25 May 2009. This 
prospective blinded (for observer and patient) cohort study was registered at http://www.
trialregister.nl (NTR2328) before onset of participant enrollment. Patients were informed 
about the study verbally and in writing and written informed consent was obtained from all 
patients. The study was conducted at the Sint Maartenskliniek Nijmegen, The Netherlands 
according to the Declaration of Helsinki and later revisions thereof and in accordance with 
the ICH guidelines for Good Clinical Practice.
Patients
Patients scheduled for cuff-, stability repair or acromioplasty of the shoulder under 
continuous brachial plexus block were assessed for eligibility during the preoperative 
screening visit. Eligible participants were all adults aged 18 or over with ASA physical 
health classi!cation I-III. None of the patients were known with a history of alcohol/drug 
dependence or abuse or with hepatic or renal insuf!ciency. Exclusion criteria included 
contra-indications for regional anesthesia (infection at the injection site, coagulopathy), 
known hypersensitivity to amide-type local anesthetics or opioids, known history of 
peripheral neuropathy, use of chronic analgesic therapy, and inability to understand 
numerical pain scores or to operate a Patient-Controlled Analgesia (PCA) device.
Anesthetic procedure
Intravenous access and routine monitoring were established in all patients. Using ultrasound 
guidance (LOGIQ e 12L-RS probe, GE Healthcare, Wauwatosa, USA), a short axis view, and 
in-plane approach, in combination with nerve stimulation, a 5 cm insulated Tuohy needle 
(Arrow, Tele"ex Medical BV, Hilversum, The Netherlands) was inserted in the interscalene 
area by an anesthesiologist experienced in ultrasound-guided interscalene block. After 
obtaining a correct needle position as determined by ultrasound and a motor response of 
deltoid, triceps or biceps muscle with a stimulus below 50 nC (0.1 ms, < 0.5 mA), a stimulating 
catheter (Arrow StimuCath, Tele"ex Medical BV, Hilversum, The Netherlands) was inserted 
2-5 cm past the needle tip without stimulation; i.e. as if it were a non-stimulating catheter. 
We de!ned the MEC as the minimal electrical charge with which a motor response of a 
muscle innervated by the brachial plexus could be elicited. After determination of the MEC, 
brachial plexus block was established by injecting a total volume of 20 mL ropivacaine 0.75% 
in fractionated doses through the catheter. Time was designated t = 0 upon conclusion of 
the loading dose. Sensory block of the shoulder was assessed using loss of sensation to pin 
prick 30 min after injection if possible without compromising operating room (OR) logistics. 
Sensory block was scored as absent, partial or complete. Surgery was performed under 
general anesthesia with propofol, remifentanil and a laryngeal mask airway.
Clinical assessments
After removal of the needle and !xation of the catheter and before administration of the 
loading dose, the MEC at the tip of the catheter necessary to evoke a motor response was 
determined and registered. If no response was present on the maximum current intensity 
of 1 mA at 0.1 ms, the pulse width was increased to 0.3 ms and then to 1.0 ms, the electrical 
charge thus varying from 0 to 1000 nC (nC = mA × ms ×1000); if no response was obtained at 
1000 nC, the current scale was increased to 5 mA and a motor response was sought up to a 
maximum electrical charge of 5000 nC. The observer of motor response (KS) was blinded for 
the electrical charge. 
One hour after administration of the brachial plexus loading dose, a continuous infusion of 
ropivacaine 0.2% 8 mL.h-1 was connected to the brachial plexus catheter and maintained 
until t = 24 h. Upon arrival in the recovery, the pain score (numerical rating scale: NRS 
0-10) was noted and a PCA morphine device set up to deliver incremental doses of 1 mg of 
morphine with a lockout time of 5 minutes and no background infusion was connected to the 
intravenous cannula. Patients were instructed in the use of the PCA device preoperatively to 
maintain postoperative pain scores (NRS) at or below 3.
At t = 24h, the continuous infusion through the catheter was stopped and the PCA device 
was disconnected by the investigator (KS). The total amount of administered morphine was 
registered. Patients were asked for their NRS at time of disconnection and their average and 
maximal NRS during the studied 24 h.
Primary outcome measures include the MEC necessary to evoke an appropriate motor 
response at the tip of the blindly inserted stimulating catheter and PCA morphine 
consumption during the !rst 24 h. 
Sample size and statistical analysis
In the absence of relevant data considering variation in electrical charge, we assumed ρ = 
0.5 the smallest correlation to be relevant. The sample size needed for this correlation with 
α = 0.05 and a power of 0.9, was calculated to be 34 patients. To compensate for drop-out, we 
chose to include 40 patients in our study.
Data were analyzed using the GraphPad Prism 6 software (GraphPad Software Inc, San Diego, 
CA). Data are presented as mean (SD) [range] or proportions. Statistical analysis used the 
Spearman’s Rho for correlation coef!cient calculation.
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Results
Forty patients were included. One patient showed symptoms of systemic toxicity (tinnitus, 
metallic taste) after 14 mL of ropivacaine 0.75% through the interscalene catheter. Injection 
was discontinued and the catheter was removed. The patient was treated with oxygen 
and prophylactic intravenous administration of lipid emulsion. No further treatment was 
necessary, symptoms resolving completely within a few minutes. Measured MEC at the tip of 
the catheter in this patient was 1425 nC.
The protocol was violated in another 5 patients. One patient mistakenly received a loading 
dose of 30 mL instead of 20 mL. In one patient the catheter was removed postoperatively 
because the patient was uncomfortable with it; later, this patient received an additional 
single shot interscalene block with 20 mL ropivacaine 0.2% because of pain; MEC in this 
patient was 72 nC. Three patients received an additional bolus of ropivacaine through the 
interscalene catheter immediately upon arrival at the recovery because of high pain scores. 
MEC values in these patients were 46, 68 and 120 nC respectively. These three patients had 
a complete sensory block of the shoulder prior to surgery. The six patients with protocol 
violations (Table 1) were excluded from subsequent analysis. 
Table 1. Protocol Violations
Event MEC* (nC)
Toxic reaction after 14 mL loading dose ropivacaine 0.75% 1425
Loading dose of 30 instead of 20 mL ropivacaine 0.75% 46
Catheter discomfort and postoperative pain (catheter removed, 
single shot interscalene block with ropivacaine 0.2%)
72
Postop pain requiring extra ropivacaine (20 mL ropi 0.2%) 46
Postop pain requiring extra ropivacaine (10 mL ropi 0.75%) 68
Postop pain requiring extra ropivacaine (20 mL ropi 0.2%) 120
*MEC = Minimal electrical charge necessary to elicit an appropriate motor response. 
Patient and surgical characteristics of the 34 patients in study are shown in Table 2.
All patients showed an appropriate motor response (deltoid, biceps or triceps muscle) during 
catheter stimulation, except for 2; one patient showed a phrenic nerve response and one 
patient had a response of the median nerve (!nger "exion). 
Table 2. Patient and Surgical Characteristics
Total (n = 34)
Sex; M/F 20/14
Age; years 49 (14)
BMI; kg.m-2 27 (4)
Duration of surgery; min 47 (16)
Type of surgery Open rotator cuff repair (n = 12)
Capsular shift (n = 11)
Scopic acromioplasty (n = 4)
Scopic rotator cuff repair (n = 2)
Latissimus dorsi transfer (n = 2)
Open acromioplasty (n = 1)
Open Bankart repair (n = 1)
Latarjet slap repair (n = 1)
Values are numbers or mean (SD) 
Sensory block of the shoulder at 30 min after injection could be assessed in 19 patients. In 
the remaining 15 patients surgery had already started before this time point. There were no 
postoperative complications related to the anesthetic procedure.
In three patients a different PCA device was mistakenly connected, with a continuous 
infusion of morphine 0.5 mg.h-1. Because these patients still required extra morphine boluses, 
they were not excluded from analysis. Total administered amount of morphine in these 
patients was 10, 23 and 27.7 mg; MEC values were 246, 38 and 60 nC respectively.
Mean morphine consumption was 8.9 (9.9) [0-29] mg (95% CI of the mean 5.4 to 12.3, n = 34). 
Data on individual parameters and clinical outcome measures are summarized in Tables 3 
and 4 respectively. Spearman’s Rank Correlation Coef!cient between the electrical charge 
(nC) at the tip of the catheter and morphine consumption was rs= -0.26 (95% CI -0.56 to 0.09, 
n = 34). Figure 1 shows a scatterplot of morphine consumption as a function of the electrical 
charge at the tip of the catheter in individual patients.
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Fig. 1. 
Scatterplot of morphine consumption related to the electrical 
charge at the tip of the catheter in individual patients. Note that 
the X-axis is not linear. 
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Table 3. Individual Outcome Parameters
M/F Response* Sensory block 
at 30 min
NRS Recovery** 24 h Morphine 
consumption; mg
MEC††; nC
F MD† complete 0 7 30
F MD complete 0 23 38
M MD unable¶ 6 29 42
F MB‡ unable 2 4 42
M MT§ complete 0 1 42
M MB complete 0 28 52
M MT complete 4 21 56
F MT complete 4 28 60
F MD unable 0 26 62
M MD partial 0 0 65
F MT complete 0 1 66
F MB unable 4 15 70
M MB unable 0 0 74
M MB unable 0 1 80
M MT unable 0 17 80
M MB unable 0 0 80
M MT complete 0 4 92
F MT complete 0 3 94
M MD unable 0 1 100
M MT unable 0 3 100
F MT partial 0 6 100
M MT complete 0 0 114
M MB unable 0 9 140
M MD complete 0 0 150
F MB complete 0 4 180
M MT complete 0 0 186
M MT unable 0 9 216
F Median nerve complete 5 10 246
F MB unable 0 3 255
F MD complete 0 6 800
F MT unable 0 18 1300
M MT partial 0 1 5000
M MB unable 0 0 5000
M Phrenic nerve partial 0 24 5000
*Response = motor response to nerve stimulation. †MD = Deltoid muscle; ‡MB = Biceps muscle;  
§MT = Triceps muscle. ¶Unable = Sensory block assessment at 30 min. not possible because patient 
already in surgery. **NRS recovery = numerical rating scale for pain upon arrival in the recovery room; 
††MEC = Minimal electrical charge necessary to evoke an appropriate motor response. 
Table 4. Clinical Outcome Measures
Total (n = 34)
MEC (nC) 589 (1414) [30 – 5000]
NRS* recovery 0.7 (1.7) [0 – 6]
NRS t = 24h 2.1 (2.1) [0 – 7]
NRS average during 24h 2.5 (2.0) [0 – 7]
NRS max during 24 h 3.9 (2.8) [0 – 9]
Morphine consumption; mg 8.9 (9.9) [0 – 29]
Values are mean (SD) [range]. *NRS = numeric rating scale for pain. 
Discussion
The purpose of our study was to investigate the hypothesis that the relation between MEC 
and morphine consumption is proportional. We found no correlation between the minimal 
electrical charge at the tip of the stimulating catheter necessary to evoke an appropiate 
motor response and the ef!cacy of the PNB catheter for brachial plexus block.
The theoretical advantage of a stimulating catheter is that if stimulation of the catheter tip 
with a low charge elicits an appropriate motor response, correct catheter position at the 
time of stimulation may be assumed, although catheter tip migration at a later stage may 
of course still occur. One of the problems associated with continuous PNB is postoperative 
pain as a result of malfunctioning of the PNB catheter. The tip of the PNB catheter being too 
far away from the target nerves to establish effective pain relief may already occur during 
catheter insertion, or it may be caused by catheter tip migration during or after surgery. In 
our study the loading dose was administered through the catheter prior to surgery and the 
observation that four patients with a MEC less than 100 nC had pain scores at or above 4 
upon arrival in the recovery room indicates that the interscalene block in these patients was 
insuf!cient despite a low MEC. 
Stimulating catheters are more expensive than non-stimulating catheters, but the literature 
is mixed regarding the bene!cial effects of the former. Some authors report advantages 
such as a shorter onset time, better postoperative analgesia or reduced postoperative 
local anesthetic and/or morphine consumption.8,9 A semiquantitative systematic review 
found evidence for better postoperative analgesia with stimulating catheters.10 Others 
fail to identify bene!ts of stimulating catheters and report no differences compared 
with traditional non-stimulating catheters.11,12 Stevens et al. reported no differences in 
postoperative pain when comparing stimulating versus non-stimulating catheters for 
continuous interscalene block, but better functional outcome six weeks after surgery.13
There is debate about the negative predictive value of nerve stimulation and the proximity 
of the needle tip to the nerve. Perlas et al. noticed that occasionally a motor response to 
nerve stimulation up to 1.5 mA (150 nC) may be absent despite needle-nerve contact as 
observed by ultrasound.14 In a study comparing the sensitivity of paresthesia and a motor 
response to nerve stimulation with an electrical charge of 50 nC or less, the sensitivity to 
nerve stimulation was 74.5% to detect needle-nerve contact as observed by ultrasound.6 
Using stimulating catheters and ultrasound as a reference, Altermatt et al. found that the 
sensitivity of an electrical charge of 50 nC to identify catheter-nerve contact was 64%.4 
Tsai et al. reported that with intraneural needle placement as determined by ultrasound, a 
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motor response could be evoked with an average stimulus of 0.56 mA (56 nC), but in 12.5% 
of the cases the MEC ranged from 80-180 nC.3 In a study quantifying the motor response 
with ultrasound-guided interscalene block, Sinha et al. found no differences in block 
characteristics between the stimulus eliciting a motor response being above or below 0.5 
mA (50 nC).15 The absence of correlation between the MEC and postoperative morphine 
consumption found in this study indicates that the MEC has no predictive value about the 
postoperative ef!cacy of the PNB catheter.
The rationale for the extra cost of a stimulating catheter is in its positive predictive value, 
i.e. the association between an appropriate motor response following a MEC at or below 
a prede!ned level, and the incidence of a properly positioned PNB catheter as determined 
f.e. by postoperative PCA morphine consumption. The results of our study show that the 
positive predictive value of a lower MEC is not associated with a reduction in morphine 
consumption, indicating that the possibility of catheter tip stimulation does not result in a 
clinically relevant advantage. This indicates that the extra cost of a stimulating catheter is 
not balanced by a better ef!cacy of the catheter.
Our study has several limitations. Due to OR logistics, sensory block could not be assessed at 
30 min in 15 patients because surgery had already started at that time. However, since the 
primary outcome parameter was the ef!cacy of the PNB catheter as determined by  
24 h morphine consumption, verifying sensory block at 30 min was not strictly necessary.  
In addition, 12 of these 15 patients had an adequate sensory block upon arrival at the 
recovery, as judged by a NRS of 0.
PCA morphine consumption as a measure of PNB catheter ef!cacy may be criticised as it 
is an indirect tool at best; morphine consumption re"ects the intensity of postoperative 
pain, but patients may use the PCA device for other discomforts as well. However, it is less 
time-consuming and less bothersome for patients than pin-prick assessments of sensory 
block at regular intervals, and in general the relation between morphine consumption and 
postoperative pain will be proportional. 
It may be argued that we did not investigate PNB catheter ef!cacy per se because the effect 
of the loading dose alone will last 8-12 h, but may last as long as 20 h and we measured 
morphine consumption only up to 24 h. However, since the loading dose was administered 
through the PNB catheter after positioning the catheter and determining the MEC, we 
believe that our !ndings adequately re"ect the relation between MEC and catheter ef!cacy.
In conclusion, our results show that in interscalene brachial plexus block the MEC at the 
catheter tip necessary to evoke an appropriate motor response has no correlation with 
catheter ef!cacy as determined by postoperative 24 h morphine consumption. 
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General discussion, future perspectives and conclusions
The main purpose of this thesis was to investigate different factors determining the duration 
of peripheral nerve blockade. In this chapter our main !ndings are summarized and 
discussed in relation to the current literature, potential limitations and clinical implications 
of the studies performed are described and recommendations for future research are given. 
Finally, the conclusions of this thesis are presented.
Discussion of main "ndings
The most important prerequisites for the use of peripheral regional anesthesia in daily 
clinical practice are success rate and safety. From a safety perspective a lower dose 
is preferable and using ultrasound guidance, adequate peripheral nerve block can be 
established with a lower volume. However, the effect of dose reduction on block duration 
was previously unknown. Recent literature has focused on the relation between volume, 
concentration and dose of local anesthetic and pharmacodynamic parameters such as 
duration of sensory and motor block. Some studies found a positive correlation between 
volume of local anesthetic and duration of postoperative analgesia. In these studies, the 
higher volume was associated with a higher dose as well.1,2 Serradell et al.3 compared the 
number of complete sensory blocks for different volumes (20, 28, 36 mL) of mepivacaine 1% in 
axillary block and found no differences in success rate, onset time and duration of analgesia 
among the 3 groups. The results suggest that 200 mg mepivacaine in a volume of 20 mL also 
provides adequate axillary block and that increasing the volume/dose of mepivacaine tot 
280 or 360 mg does not result in a higher success rate or al longer duration of analgesia. In a 
dose-ranging study of 0.5% bupivacaine and ropivacaine for sciatic nerve block, Nader et al.,4 
found that injection volumes greater than or equal to 10 mL produced complete sensory and 
motor block within 30 minutes. Volumes greater than 10 mL did not extend the duration of 
the sensory or motor block. Injection volumes of 2.5 and 5 mL were associated with delayed 
onset and decreased block duration and a greater fraction of subjects experiencing pain 
behind the knee. 
In Chapter 2, a local anesthetic dose reduction of 62.5% resulted in an approximate 17% 
shorter overall sensory and 19% motor block duration, and a reduction in time to !rst request 
for postoperative analgesia (TTFR) of approximately 30%. The difference in block duration 
observed in Chapter 2 was the effect of either a reduction in volume from 40 to 15 mL 
mepivacaine 1.5%, a reduction in dose from 600 to 225 mg mepivacaine, or a combination of 
both. 
In Chapter 3 we describe the results of a follow up study on the effect of local anesthetic 
concentration, dose and volume on the duration of single shot ultrasound-guided axillary 
brachial plexus block with mepivacaine. We compared the effects of different doses in equal 
volumes (30 mL mepivacaine 1% and 30 mL mepivacaine 1.5%) as well as equal doses in 
different volumes (20 mL mepivacaine 1.5% and 30 mL mepivacaine 1%) for axillary brachial 
plexus block. Our results show that the higher dose (and concentration) administered in 
Group 30 mL mepi 1.5% resulted in a longer duration of sensory and motor block as compared 
to Group 30 mL mepi 1%. A remarkable !nding of our study was a tendency for a longer 
duration for sensory and motor block in Group 20 mL mepi 1.5% as compared to Group 30 mL 
mepi 1%, both for overall duration (approximately 13% and 15%) as well as for the individual 
nerves (values ranging from 9-16% and 10-22% for duration of sensory and motor block 
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respectively). This may indicate that when using equal doses, a higher concentration/lower 
volume results in longer duration. In a study using multivariate Cox regression to assess the 
effect of different volumes and concentrations of ropivacaine on the duration of analgesia 
following interscalene block for shoulder surgery, Fredrickson et al.5 concluded that both 
volume and concentration affect duration independently. More recently, Cappelleri et al.6 
compared duration of sensory block with 12 mL mepivacaine 2% (240 mg) versus 24 mL 
mepivacaine 1% (240 mg) for double injection sciatic nerve block and found no indication 
for altered onset time and block duration. These latter data suggest that total dose of local 
anesthetic is the main determinant of peripheral nerve block duration.
In Chapter 3, reducing the volume/dose from 30 mL mepivacaine 1.5% (450 mg) to 20 mL 
mepivacaine 1.5% (300 mg) did not result in a shorter duration of sensory or motor block. 
Combining the observations from Chapter 2 and 3, it seems clear that the relation between 
a reduction in dose and the duration of nervous blockade is not proportional. Reducing the 
dose of mepivacaine 1.5% from 600 mg (40 mL) to 300 mg (20 mL) results in a modest change 
in the median duration of nervous blockade of approximately 5%; a further decrease to 
225 mg (15 mL) or a decrease in concentration to 1% (300 mg, 30 mL) results in a decrease 
in duration of approximately 18% and 15% respectively. It seems therefore that in axillary 
brachial plexus block, the optimal balance between dose reduction without signi!cantly 
affecting duration of nervous blockade lies around 20 mL mepivacaine 1.5%. 
From the above-described !ndings we conclude that for a particular block, a minimum 
amount of a speci!c local anesthetic is necessary for an adequate nerve block and increasing 
dose or volume will not extend the duration of sensory or motor block. In a recent review, Eng 
et al also concluded that there appears to be a dose threshold beyond which improvements 
in onset time, block intensity and analgesic duration become less signi!cant.7 
Despite the aim for dose reduction to enhance safety, in case of lower limb surgery a 
combination of blocks and consequently higher doses of local anesthetics is often necessary. 
Chapter 4 was the !rst study describing the pharmacokinetic pro!le in serum of 450 mg 
ropivacaine with and without epinephrine for combined sciatic/femoral nerve block. Patients 
received 60 mL ropivacaine either without (Group R) or with epinephrine 5 μg/ml (Group 
RE). Obviously the major concern when using high doses of local anesthetic is systemic 
toxicity. Ropivacaine has a high degree of protein binding in plasma (94%)8, mainly to α-1 
acid glycoprotein. As only unbound ropivacaine is capable of passing membranes, the free 
ropivacaine concentration in serum is the determinant of local anesthetic-related central 
nervous system and cardiac toxicity. Knudsen et al.9 previously de!ned the toxic threshold 
for free ropivacaine in arterial samples as 0.56 [0.34-0.85] μg/mL. The average maximum 
free ropivacaine serum concentration in our study was 0.16 ± 0.08 [0.07-0.30] μg/mL in 
group R and 0.12 ± 0.04 [0.09-0.17] μg/mL in group RE. Total and free serum concentrations 
of ropivacaine remained well below the assumed threshold for local anesthetic systemic 
toxicity. The addition of epinephrine prolonged tmax signi!cantly, but the difference in 
Cmax was statistically not signi!cant. Several other studies found a decrease in Cmax and an 
increase in tmax as a result of adding epinephrine to ropivacaine for epidural10,11, caudal12, or 
regional (thoracic paravertebral block)13 anesthesia.
Although the number of subjects in our study does not allow conclusions on the issue of 
safety, in the past 10 years, more than 5,000 patients at our institution have received a 
combined sciatic/femoral nerve block with 450 mg of ropivacaine. During this period, we 
have observed only one patient with mild signs of delayed systemic toxicity (anxiety and 
restlessness, 45 min after injection) that resolved within minutes without treatment. The 
results of Chapter 4 support our clinical experience that a combined sciatic/femoral nerve 
block with 450 mg ropivacaine in adult patients > 70 kg and < 60 years is safe. 
To prevent the need for larger doses of local anesthetic, in recent literature several adjuncts 
have been tested with single-shot peripheral nerve block in order to prolong duration of 
analgesia. F.e. perineural dexamethasone (4 or 8 mg) prolongs the duration of analgesia after 
local anesthetic peripheral nerve block and reduces cumulative morphine consumption and 
PONV without serious side effects.14 However, postoperative infection rate may increase 
and further studies are needed to de!ne the best route of administration (iv vs. perineural) 
and optimal balance between dose, effects and side effects. Moreover, none of the adjuncts 
have been approved for perineural use, therefore caution is recommended concerning side 
effects and potential neurotoxicity. Nonetheless, Kirksey et al.15 recently concluded in a 
systemic qualitative review that buprenorphine, clonidine, dexamethasone, magnesium and 
dexmedetomidine are promising agents for use in prolongation of local anesthetic peripheral 
nerve blocks.
In Chapter 4 we found a median time to !rst request of analgesia (TTFR) of 17 [12.5-22] h in 
Group RE and 3.5 [3-17] h in the Group R, suggesting a prolonged duration of action when 
adding epinephrine. The difference in TTFR between the groups in Chapter 4 was statistically 
not signi!cant and because our study was not powered to make comparisons, these data 
have not been published. Therefore we designed the study in Chapter 5 to investigate if the 
addition of epinephrine would result in signi!cant lengthening of the TTFR.
In Chapter 5 we were unable to con!rm this expected difference in the duration of 
postoperative analgesia by adding epinephrine 5 μg/ml to 30 mL ropivacaine 0.75% for 
popliteal nerve block. The difference in the median TTFR between the groups was large (367 
min), but the data were not normally distributed and showed a large variation. Therefore, 
the Hodges Lehman estimate of the median difference between groups is a better utility. 
This was 71 min (95% CI -415 – 473). The absence of a signi!cant difference may be explained 
on the basis of the intrinsic vasoconstrictive properties of ropivacaine. However, it may also 
be caused by a Type II error due to a large interindividual variation in TTFR. Similarly, Weber 
et al.16 found no difference in time to !rst request for postoperative analgesia between 
ropivacaine 0.5% with and without epinephrine for femoral nerve block. 
In contrast, other studies have found a signi!cantly longer duration of postoperative 
analgesia when adding epinephrine to short or intermediate acting local anesthetics. 
Kämmerer et al.17 described signi!cantly longer patient reported duration of soft tissue 
anesthesia when using articaine 4% with vs. without epinephrine 1:100,000 for inferior 
alveolar block. Comparably, Dogru et al.18 found a signi!cantly longer time to !rst sensation 
of pain after axillary brachial plexus block with 35 mL lidocaine 1.5% with either 25 or 200 μg 
of epinephrine as compared to lidocaine alone. Furthermore, Song at al.19 found signi!cantly 
extended duration of sensory and motor block and time to !rst pain sensation when adding 
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epinephrine 1:200,000 to 40 mL mepivacaine 1% as compared to mepivacaine alone for 
infraclavicular brachial plexus block. 
Epinephrine is believed to prolong duration of analgesia because it slows absorption of local 
anesthetics at the site of injection due to vasoconstriction. This suggests that epinephrine 
does not prolong duration of postoperative analgesia when added to ropivacaine, due to 
intrinsic vasoconstrictive properties of the latter. 
As described in Chapter 1, another method of providing prolonged duration of analgesia 
is by inserting a perineural catheter for continuous infusion of low dose local anesthetic. 
The analgesic ef!cacy of continuous postoperative peripheral nerve block depends on 
correct placement of the perineural catheter, i.e. in proximity to the nerve. Stimulating 
catheters offer the possibility of nerve stimulation via the tip of the catheter. This may be 
advantageous, because placement of the catheter tip close to the nerve can be veri!ed by a 
correct motor response following electrical stimulation. However, stimulating catheters are 
more expensive. 
Cappelleri et al, following the study of Paqueron et al.20, recently demonstrated that use of 
a stimulating catheter halved the EV50 (minimum effective anesthetic volume in 50% of 
patients) of mepivacaine 1.5% required for lumbar plexus block when the local anesthetic 
was injected through the catheter, compared with a conventional non-stimulating 
catheter.21
The results in Chapter 6 show that in interscalene brachial plexus block the minimal 
electrical charge (MEC) at the catheter tip necessary to evoke an appropriate motor response 
has no correlation with catheter ef!cacy as determined by postoperative 24h morphine 
consumption after cuff-, stability repair or acromioplasty of the shoulder. Mean morphine 
consumption was 8.9 (±9.9) [0-29] mg (95% CI of the mean 5.4 to 12.3 mg, n = 34) in the 24h 
study period. This indicates adequate pain relief with the use of a continuous brachial plexus 
block after shoulder surgery. The absence of correlation between the MEC and postoperative 
morphine consumption found in Chapter 6 indicates that the MEC has no predictive value 
about the postoperative ef!cacy of the peripheral nerve block catheter. This means that 
the extra cost of a stimulating catheter as compared to a non-stimulating catheter is not 
balanced by a better performance.
When using ultrasound guidance, nerve stimulation may no longer be a prerequisite for 
optimal placement. Recent literature has focused on the added value of using a stimulating 
catheter in combination with ultrasound guidance. Brooks et al.22 found no differences with 
regard to catheter visibility, block onset or success rate of ultrasound-guided continuous 
sciatic nerve block with either stimulating needle and catheter or echogenic needle and 
catheter. However, the stimulating group required more needle redirections, had a longer 
procedure time and greater patient discomfort. Farag et al.23 compared ultrasound guidance 
alone with either ultrasound guidance plus needle stimulation or ultrasound guidance plus 
catheter stimulation for insertion of femoral nerve catheters for total knee arthroplasty and 
found no superiority of one method over another in pain scores or opioid requirement. Block 
performance time was shorter and costs were lower for the ultrasound-alone group.
Besides, from a safety perspective, there is an expanding body of literature describing 
stimulating catheter entrapment.24 Taking all this into consideration, we come to the 
conclusion that when using ultrasound guidance, there is no added value for stimulating 
catheters in current practice. Many aspects of continuous peripheral nerve block need 
further research including optimal catheter insertion techniques, infusate(s) and adjuvants, 
details of optimizing ambulatory infusions, and prevention of rare adverse effects.25 
Potential limitations
There are several limitations in the design of the studies described in this thesis. 
When investigating duration of peripheral nerve block, sensory and motor block testing at 
regular time intervals (as done in Chapter 2 and 3) is the most objective method. TTFR, as used 
in Chapter 4 and 5, is a subjective measure of duration of analgesia. However, when using 
long acting local anesthetics like ropivacaine, offset testing would take 24 – 48 h, including 
nighttime measurements, which is bothersome for patients. Furthermore, from a clinical 
perspective, duration of analgesia may be more important than duration of sensory block. In 
Chapter 6, we use morphine consumption as a measure of catheter ef!cacy, which also is an 
indirect tool at best. However, in general, the relation between morphine consumption and 
postoperative pain will be proportional and we therefore believe that this method was valid.
A second limitation is the probability of lack of power in Chapters 3 and 5. For both studies, 
a power analysis was performed based on data found in the existing literature and we 
compensated for possible larger variations in standard deviation. In Chapter 3, our power 
analysis was based on a clinically relevant difference of 60 min, whereas in retrospect and 
from a scienti!c perspective smaller differences may also be interesting. As a result of the 
large variation in our data in Chapter 5, the risk of a Type II error is considerable. Possibly 
larger sample sizes would have unveiled signi!cant differences. This also accounts for the 
difference in Cmax and TTFR as described in Chapter 4, although this was a pilot study, not 
powered to make comparisons. 
And last, with the advances in ultrasound, there has been a rapid re!nement in block 
placement techniques. In Chapters 2, 3 and 4, relatively high concentrations of mepivacaine 
(450 and 600 mg) and ropivacaine (450 mg) are being used. The use of ultrasound allows for 
a reduction in local anesthetic dose without compromising block characteristics. However, 
exceeding the maximum recommended dose of ropivacaine and mepivacaine still occurs 
regularly. As such there remains a need for pharmacokinetic and -dynamic data on doses that 
are higher than the maximum recommended dose. Authoritative statements about safety 
obviously require larger numbers. 
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Clinical implications
The results of the studies described in this thesis may have various implications for clinical 
practice. With regard to the effect of dose reduction on peripheral nerve block duration, our 
results suggest that when using equal doses, a higher concentration/lower volume results 
in a longer duration, but total dose seems to be the main determinant of peripheral nerve 
block duration. However, our !ndings also suggest that there is a threshold dose of local 
anesthetic: increasing the dose above this threshold will not result in a further increase in 
the duration of sensory or motor block. 
In case of multiple nerve blocks, the usage of higher than recommended doses (up to 450 
mg ropivacaine or 600 mg mepivacaine for patients > 70 kg and < 60 years of age) seems to 
be safe. Epinephrine may be added to ropivacaine in order to enhance safety, but it has no 
bene!cial effect on block duration. Lastly, our results indicate that, when using a stimulating 
catheter, the MEC has no predictive value on the postoperative ef!cacy of the peripheral 
nerve block catheter.
Future Perspectives
Current clinical practice in (orthopedic) surgery is shifting towards the patient not being 
‘ill’, but rather being seen as a healthy person in need of some ‘repairment’. This 'fast-track 
surgery' or 'fast-track rehabilitation', consists of several elements such as preoperative 
education, minimally invasive surgery, optimal pain relief, and early mobilization. The goal 
of modern anesthetic techniques is to facilitate a short recovery time and to minimize 
postoperative nausea and vomiting and pain. Optimal control over postoperative pain is 
a determining factor for the success of fast-track rehabilitation and ambulatory care and 
regional anesthetic techniques in combination with a multimodal pain regimen play a vital 
role. Trend analyses show that peripheral nerve blocks are increasingly being used in both 
inpatient and ambulatory orthopedic surgery.26 However, adequate pain relief by means of 
peripheral nerve block may hamper the goals of early mobilization and early discharge.
Future research should focus on !nding the optimal balance between adequate analgesia 
and minimal interference with the prerequisites of fast-track rehabilitation. Several issues 
come into view, like !ne-tuning of multimodal analgesic regimens in combination with a 
peripheral nerve block. Secondly, the optimal drug and dose for individual blocks should be 
de!ned: further research is necessary to determine whether a threshold dose exists above 
which pharmacodynamic parameters do not further improve signi!cantly. 
From a safety perspective, future research should focus on prolonging duration of analgesia 
without the need for larger doses of local anesthetics. This may be accomplished by 
investigating non-neurotoxic additives to local anesthetics that provide a more differential 
block, i.e. prolonging the duration of sensory block without affecting the duration of motor 
block. Furthermore, strategies for safe mobilization in the presence of a partial motor block 
should be developed as well as protocols for safe discharge of patients with a functional 
peripheral nerve catheter. To prevent the need for a perineural catheter, further research 
could focus on local in!ltration of multivesicular liposomes containing bupivacaine, which 
may have promising implications for prolonged postoperative analgesia. 
Last but not least, there are clear indications that severe postoperative pain predisposes to 
the development of chronic pain, which has major social and economical implications. Since 
peripheral nerve block is capable of providing optimal postoperative pain relief, this may be 
associated with a reduction of the incidence or severity of chronic pain following surgery. 
Long-term outcome studies are necessary to substantiate this.
Conclusions 
The main conclusions that can be drawn from the results of the studies presented in this 
thesis are:
- In axillary brachial plexus block with mepivacaine 1.5%, volume reduction from 40 mL to 
15 mL (62.5%) shortens the overall duration of sensory and motor block by approximately 
17-19% and reduces sensory and motor block duration of individual nerves with 18-40%. 
(Chapter 2)
- In axillary brachial plexus block with mepivacaine 1.5%, volume reduction from 40 to 15 mL 
(62.5%) decreases the time to !rst request for postoperative analgesia by approximately 
30%. (Chapter 2)
- A higher dose (and concentration) of mepivacaine results in a longer duration of sensory 
and motor axillary brachial plexus block. (Chapter 3)
- It seems that in axillary brachial plexus block, the optimal balance between dose reduction 
without signi!cantly affecting duration of nervous blockade is 20 mL mepivacaine 1.5%. 
(Chapter 3)
- Total and free serum concentrations of ropivacaine after a combined sciatic/femoral nerve 
block with 450 mg ropivacaine with or without epinephrine 1:200,000 remain well below 
the assumed threshold for local anesthetic systemic toxicity. (Chapter 4)
- The addition of epinephrine to ropivacaine 0.75% for popliteal nerve block does not result 
in an extension of the duration of postoperative analgesia. (Chapter 5)
- In interscalene brachial plexus block the minimal electrical charge at the tip of a 
stimulating catheter necessary to evoke an appropriate motor response has no correlation 
with catheter ef!cacy as determined by postoperative 24h morphine consumption. 
(Chapter 6)
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Summary 
Peripheral nerve block (PNB) is popular among anesthesiologists and patients for peri- and 
postoperative pain relief. Chapter 1 describes the relevant anatomy, techniques and local 
anesthetics used for peripheral nerve blocks. Duration of peripheral nerve block depends 
on several factors such as the choice of local anesthetic (LA), the presence of adjuncts such 
as epinephrine, and the use of a catheter for prolonged infusion. Choices can be made 
dependent on the purpose of the nerve block; is it for intraoperative anesthesia and/or 
should it provide (prolonged) postoperative analgesia.
Intraoperative anesthesia for minimally painful surgery: short acting local anesthetics
The most important prerequisites for the use of peripheral regional anesthesia in daily 
clinical practice are success rate and safety. From a safety perspective a lower dose 
is preferable and using ultrasound guidance, adequate peripheral nerve block can be 
established with a lower volume. However, the effect of dose reduction on block duration 
was previously unknown. 
In Chapter 2, we compared the duration of sensory and motor axillary brachial plexus block 
with 15 or 40 mL mepivacaine 1.5%. A local anesthetic volume reduction of 62.5% resulted in 
an approximate 17% shorter overall sensory and 19% motor block duration, and a reduction 
in time to !rst request for postoperative analgesia (TTFR) of approximately 30%. 
In Chapter 3 we describe the results of a follow up study on the effect of local anesthetic 
concentration, dose and volume on the duration of single shot ultrasound-guided axillary 
brachial plexus block with mepivacaine. Our results show that the higher dose (and 
concentration) administered in Group 30 mL mepi 1.5% resulted in a longer duration of 
sensory and motor block as compared to Group 30 mL mepi 1%. We found no difference in 
duration between 20 or 30 mL mepi 1.5%. A notable !nding of our study is a tendency for a 
longer duration for sensory and motor block in Group 20 mL mepi 1.5% as compared to Group 
30 mL mepi 1%.
Intraoperative anesthesia and postoperative analgesia: long acting local anesthetics with 
additives
For surgery where some postoperative pain is expected, a longer acting local anesthetic 
can be used. This can provide surgical anesthesia and cover the !rst postoperative hours in 
terms of postoperative analgesia. In case of lower limb surgery a combination of blocks and 
consequently higher doses of local anesthetics is often necessary. 
Chapter 4 was the !rst study describing the pharmacokinetic pro!le in serum of 450 
mg ropivacaine with and without epinephrine for combined sciatic/femoral nerve block. 
Patients received 60 mL ropivacaine 0.75% either without (Group R) or with epinephrine 
5 μg/ml (Group RE) and venous blood samples were obtained during 48h following block 
placement. Total and free serum concentrations of ropivacaine remained well below the 
assumed threshold for local anesthetic systemic toxicity. The addition of epinephrine 
prolonged tmax signi!cantly, but the difference in Cmax was statistically not signi!cant. With 
regard to duration of analgesia, we found a large non-signi!cant difference in median time 
to !rst request of analgesia (TTFR). As our study was not powered to make comparisons, 
we designed the study in Chapter 5 to investigate if the addition of epinephrine results in 
signi!cant lengthening of the TTFR.
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In Chapter 5 we were unable to con!rm this expected difference in the duration of 
postoperative analgesia. Thirty-eight patients were included to receive ultrasound guided 
continuous popliteal nerve block with ropivacaine 0.75% either without (ROPI) or with 
epinephrine 5 μg/mL (ROPI-EPI). We compared duration of postoperative analgesia as 
re"ected by the time to !rst request for postoperative analgesia (TTFR) through the popliteal 
nerve catheter. The absence of a signi!cant difference may be explained on the basis of the 
intrinsic vasoconstrictive properties of ropivacaine. However, it may also be caused by a type 
II error due to a large variation in the individual TTFR. 
Postoperative prolonged action with a perineural catheter 
If postoperative pain is expected to be severe and longer lasting, e.g. in arthroplasty, a nerve 
catheter can be inserted for prolonged infusion of local anesthetic. For continuous nerve 
block, stimulating and non-stimulating catheters can be used. 
Chapter 6 was designed to investigate whether there is a correlation between the 
minimal electrical charge (MEC) at the tip of the stimulating catheter, and the ef!cacy of 
the interscalene brachial plexus catheter as determined by 24h postoperative morphine 
consumption. The absence of a correlation between the MEC and postoperative morphine 
consumption found in Chapter 6 indicates that the MEC has no predictive value about the 
postoperative ef!cacy of the PNB catheter. This means that the extra cost of a stimulating 
catheter as compared to a non-stimulating catheter is not balanced by a better performance.
Chapter 7 of this thesis summarizes and discusses our main !ndings in relation to the 
current literature and gives recommendations for future research.
Summary
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Perifere zenuwblokkades kunnen voor zeer goede pijnstilling zorgen tijdens en na operaties 
en zijn daarom populair bij patiënten en anesthesiologen. In hoofdstuk 1 worden de 
relevante anatomie, de technieken en de lokaal anesthetica beschreven die nodig zijn voor 
perifere zenuwblokkades (PZBs). De werkingsduur van zo’n blokkade is afhankelijk van 
verschillende factoren, zoals keuze van lokaal anestheticum (LA), het toevoegen van een 
additief zoals adrenaline en het gebruik van een zenuw katheter voor langdurige infusie. 
De keuzes worden gemaakt afhankelijk van het doel van de zenuwblokkade: moet het een 
pijnvrije operatie mogelijk maken en/of moet het postoperatief langdurig pijnstilling geven.
Intraoperatieve anesthesie voor chirurgie zonder veel pijn nadien: kort werkende lokaal 
anesthetica
De belangrijkste voorwaarden voor het gebruik van regionale anesthesie in de dagelijkse 
klinische praktijk is het succespercentage en de veiligheid. Vanuit veiligheidsoogpunt heeft 
een lagere dosis lokaal anestheticum de voorkeur. Met het gebruik van echogeleiding kan 
een adequaat blok verkregen worden met een kleiner volume LA. Desondanks was het effect 
van een dosisverlaging op de werkingsduur onbekend.
In hoofdstuk 2 hebben we de werkingsduur vergeleken van sensibel en motorisch axillair 
blok met 15 of 40 ml mepivacaïne 1.5%. Een volumereductie van 62.5% resulteerde in 
ongeveer 17% kortere sensibele en 19% kortere motorische blokkade. De tijd tot eerste vraag 
naar postoperatieve pijnstilling (TTFR) was ongeveer 30% korter.
In hoofdstuk 3 beschrijven we de resultaten van een vervolgstudie naar het effect van 
concentratie, dosis en volume van het lokaal anestheticum op de werkingsduur van 
echogeleid axillair brachiaal plexusblok met mepivacaïne. Wij vonden daarbij dat de hogere 
dosis (en concentratie) toegediend in groep 30 ml mepi 1.5% resulteerde in een langere 
werkingsduur van sensibele en motorische blokkade in vergelijking met groep 30 ml mepi 1%. 
We hebben geen verschil in werkingsduur gevonden tussen 20 of 30 ml mepivacaïne 1.5%. 
Opvallend was dat we een neiging tot langere sensibele en motorische blokkade hebben 
gevonden in groep 20 ml mepi 1.5% in vergelijking met 30 ml mepi 1%.
Intraoperatieve anesthesie en postoperatieve analgesie: lang werkende lokaal anesthetica 
met additieven
Voor operaties waar (beperkte) postoperatieve pijn voorzien is, kan een lang werkend lokaal 
anestheticum gebruikt worden. Dit zorgt voor gevoelloosheid tijdens de operatie en dekt 
de pijnstilling gedurende de eerste uren na de operatie. Voor onderbeenoperaties is vaak 
een combinatie van verschillende zenuwblokkades nodig waarbij hogere doseringen lokaal 
anestheticum gebruikt worden.
Hoofdstuk 4 beschrijft als eerste studie het farmacokinetisch pro!el in serum van 450 mg 
ropivacaïne met en zonder adrenaline voor gecombineerde femoralis/ischiadicus blokkade. 
Patiënten kregen 60 ml ropivacaïne 0.75% zonder (Groep R), dan wel met adrenaline 5 μg/ml 
(Groep RE) en veneuze bloedmonsters werden gedurende 48 uur na de blokkade afgenomen. 
Totale en vrije serum concentraties ropivacaïne bleven ruim onder de grens voor lokaal 
anesthetische systemische toxiciteit. De toevoeging van adrenaline verlengde de tijd tot 
de maximale concentratie signi!cant, maar het verschil in de maximale concentratie was 
niet signi!cant. Wat betreft duur van de pijnstilling, hebben we een groot, niet signi!cant 
verschil gevonden in mediane tijd tot eerste postoperatieve pijnstilling (TTFR). Aangezien 
deze studie niet opgezet was om een verschil hierin te kunnen vinden, hebben we de studie 
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in hoofdstuk 5 opgezet om te onderzoeken of het toevoegen van adrenaline zorgt voor een 
signi!cant langere TTFR.
In hoofdstuk 5 hebben we dit verwachtte verschil in werkingsduur van postoperatieve 
analgesie niet kunnen aantonen. Achtendertig patiënten zijn geïncludeerd voor een 
echogeleid continu poplitea blok met ropivacaïne 0.75% zonder (ROPI) of met adrenaline 
5 μg/ml (ROPI-EPI). We hebben de analgesie duur gemeten als tijd tot vraag naar eerste 
postoperatieve pijnstilling (TTFR) door de poplitea zenuwkatheter. Het niet vinden van een 
signi!cant verschil zou kunnen worden verklaard doordat ropivacaïne zelf vaatvernauwende 
effecten heeft. Het kan echter ook komen door een type II fout vanwege een grote variatie in 
TTFR tussen de verschillende patiënten. 
Postoperatief verlengde werking met een perifere zenuwkatheter
Als postoperatief langdurig pijn te verwachten is zoals bijvoorbeeld bij 
gewrichtsvervangende operaties, kan een zenuwkatheter achtergelaten worden voor 
langdurige infusie van lokaal anestheticum. Continue infusie kan gegeven worden door 
stimulatie en niet stimulatie katheters.
De studie in hoofdstuk 6 is opgezet om te onderzoeken of er een correlatie bestaat tussen 
de minimale elektrische stroom (MEC) op de punt van een stimulatie katheter en de 
doeltreffendheid van een interscaleen katheter, uitgedrukt in 24 uur postoperatieve mor!ne 
consumptie. De afwezigheid van een correlatie tussen de MEC en de postoperatieve mor!ne 
consumptie zoals gevonden in hoofdstuk 6 indiceert dat de MEC geen voorspellende waarde 
heeft met betrekking tot de postoperatieve doeltreffendheid van de zenuwkatheter. Dit 
betekent dat de extra kosten van de stimulatiekatheter niet worden gecompenseerd door 
een betere werking.
Hoofdstuk 7 van dit proefschrift geeft een samenvatting van de resultaten, bediscussieert 
de belangrijkste bevindingen in relatie tot de huidige literatuur en geeft aanbevelingen voor 
toekomstig onderzoek.
Samenvatting
107106 Dankwoord
Dankwoord
Yes, big smile :D mijn ‘boekje’ is bijna klaar! Jaren geleden ben ik aan dit avontuur begonnen 
en daar gaat nu toch echt een eind aan komen (of het is een begin van mooie nieuwe 
dingen!). In deze tijd heb ik ontzettend veel geleerd en vele leuke, mooie (soms ook 
vervelende) en leerzame ervaringen op kunnen doen. Gevoelsmatig ben ik er een veelzijdiger 
clinicus van geworden, persoonlijk ben ik zeker gegroeid. En daar ben ik veel mensen zeer 
dankbaar voor, al dat werk doe je uiteraard niet alleen.
Om te beginnen prof. dr. Scheffer (promotor), bedankt voor het in mij gestelde vertrouwen 
en de kans die ik heb gekregen om dit traject in te gaan en te kunnen voltooien. Tijdens onze 
gesprekken heeft uw kritische blik en wijze raad me telkens nieuw enthousiasme en richting 
gegeven.
Dr. Stienstra (co-promotor), beste Ruud, toen je vanuit Leiden naar de Sint Maartenskliniek 
kwam had je een visie om wetenschap binnen de afdeling anesthesiologie een vaste poot 
te geven. Ik ben trots dat ik daar als eerste arts-onderzoeker een bijdrage aan heb mogen 
leveren. Intussen zijn daar mooie projecten, publicaties en presentaties uit gekomen en is al 
de derde arts-onderzoeker bezig met haar promotie onderzoek. Jouw gedrevenheid, liefde 
voor en kennis van het vak zijn bijzonder motiverend en aanstekelijk. Ik heb ontzettend 
veel geleerd van onze wekelijkse overleg-uurtjes en kan nog altijd bij je terecht voor raad of 
gewoon een gezellig praatje :) Mijn dank is groot. Je bent als wetenschapper, clinicus en ook 
als mens een groot voorbeeld.
Dr. Heesterbeek, beste Petra, initieel was je betrokken als coördinator van OrthoResearch, 
later ook als mede auteur en uiteindelijk als co-promotor. Je bent een echte onderzoeker en 
ik kon als dokter altijd bij je terecht voor bijscholing op gebied van de wetenschap. Je frisse, 
andere perspectief heeft me vaak verder geholpen en ik wil je bedanken voor onze !jne tijd 
als collega’s en alles wat ik van je geleerd heb.
Leden van de manuscriptcommissie, prof. dr. Russel (voorzitter), prof. dr. De Kleuver en prof. 
dr. Bruhn, hartelijk dank voor de tijd en moeite om dit proefschrift te lezen en kritisch te 
beoordelen. 
Veel dank gaat naar mijn paranimfen Miranda van Hooff en José Meulepas. Miranda, als 
collega’s hebben we regelmatig ‘even kof!e gedronken’ en later ben ik een dag in de week 
bij je op de kamer komen zitten. Daarbij kon ik alles met je bespreken waar ik tegenaan 
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